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Pediatric Life Support
2020 International Consensus on Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care
Science With Treatment Recommendations
$

Ian K. Maconochie, Richard Aickin, Mary Fran Hazinski, Dianne L. Atkins,
Robert Bingham, Thomaz Bittencourt Couto, Anne-Marie Guerguerian,
Vinay M. Nadkarni, Kee-Chong Ng, Gabrielle A. Nuthall, Gene Y.K. Ong, Amelia G. Reis,
Stephen M. Schexnayder, Barnaby R. Scholefield, Janice A. Tijssen, Jerry P. Nolan,
Peter T. Morley, Patrick Van de Voorde, Arno L. Zaritsky, Allan R. de Caen, on behalf of
the [14_TD$IF]Pediatric Life Support Collaborators 1
Abstract
This 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment
Recommendations (CoSTR) for pediatric life support is based on the most extensive evidence evaluation ever performed by the Pediatric Life
Support Task Force. Three types of evidence evaluation were used in this review: systematic reviews, scoping reviews, and evidence updates. Per
agreement with the evidence evaluation recommendations of the International Liaison Committee on Resuscitation, only systematic reviews could
result in a new or revised treatment recommendation.
Systematic reviews performed for this 2020 CoSTR for pediatric life support included the topics of sequencing of airway-breaths-compressions versus
compressions-airway-breaths in the delivery of pediatric basic life support, the initial timing and dose intervals for epinephrine administration during
resuscitation, and the targets for oxygen and carbon dioxide levels in pediatric patients after return of spontaneous circulation. The most controversial
topics included the initial timing and dose intervals of epinephrine administration (new treatment recommendations were made) and the administration
of fluid for infants and children with septic shock (this latter topic was evaluated by evidence update). All evidence reviews identified the paucity of
pediatric data and the need for more research involving resuscitation of infants and children.
Keywords: AHA Scientific Statements, arrhythmia, cardiopulmonary resuscitation, child, congenital heart disease, ECMO, pediatrics

The 2020 International Consensus on Cardiopulmonary Resuscitation
(CPR) and Emergency Cardiovascular Care (ECC) Science With
Treatment Recommendations (CoSTR) is the fourth in a series of
annual publications from the International Liaison Committee on
Resuscitation (ILCOR). This 2020 CoSTR summary for pediatric life
support (PLS) includes new topics addressed by Systematic Reviews
(SysRevs) performed within the past 12 months. It also includes
updates of the PLS CoSTR statements published from 2010 through

2019 as needed, based on additional evidence evaluations. As a
result, this 2020 CoSTR summary for PLS is the most comprehensive
update since 2010. The 3 major types of evidence evaluation
supporting this 2020 publication are the SysRev, the Scoping Review
(ScopRev), and the Evidence Update (EvUp).
Topics and types of reviews were prioritized by the PLS Task Force
over the past 12 months on the basis of task force consensus that the
answers to the review questions were critical, task force expert
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awareness of recent studies on the topics that could change treatment
recommendations, and input and requests from the ILCOR member
councils. SysRevs were performed on topics if deemed critical on the
basis of the questions involved or if publication of studies suggested
the need to consider new or modified treatment recommendations.
ScopRevs and EvUps were performed if the task force or member
councils identified a topic as important or if it had not been reviewed in
several years; ScopRevs and EvUps were intended to determine if
sufficient published evidence existed to suggest the need for a
SysRev.
The SysRev is a rigorous process following strict methodology to
answer a specific question, and each of these ultimately resulted in the
generation of a task force CoSTR included in this summary. The
SysRevs were performed by a knowledge synthesis unit, an expert
systematic reviewer, or the PLS Task Force, and many resulted in
separate SysRevs publications.
To begin the SysRev, the question to be answered was phrased in
terms of the PICOST (population, intervention, comparator, outcome,
study design, time frame) format. The methodology used to identify the
evidence was based on the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA).1 The approach used to
evaluate the evidence was based on that proposed by the Grading of
Recommendations, Assessment, Development and Evaluation
(GRADE) working group.2 Using this approach, the PLS Task Force
rated as high, moderate, low, or very low the certainty/confidence in
the estimates of effect of an intervention or assessment across a body
of evidence for each of the predefined outcomes. Randomized
controlled trials (RCTs) generally began the analysis as high-certainty
evidence, and observational studies generally began the analysis as
low-certainty evidence; examination of the evidence using the
GRADE approach could result in downgrading or upgrading the
certainty of evidence. For additional information, refer to “Evidence
Evaluation Process and Management of Potential Conflicts of
Interest.”[15_TD$IF]3,3a
When a pre-2015 CoSTR treatment recommendation was not
updated, the language used in the recommendation differed from that
used in the GRADE approach because GRADE was not used before
2015.4 6
Draft 2020 (ie, new) CoSTRs for PLS were posted on the ILCOR
website7 for public comment between March 26, 2018, and January
10, 2020. The draft CoSTR statements were viewed 31,468 times with
16 comments received. All comments were discussed by the PLS
Task Force and modifications made as needed to the content or to the
recommendations for future search strategies.
This summary contains the final wording of the CoSTR statements
as approved by the ILCOR PLS Task Force and the ILCOR member
councils after review and consideration of comments posted online in
response to the draft CoSTRs. In this publication, each topic includes
the PICOST as well as the CoSTR, an expanded Justification and
Evidence to Decision Framework Highlights section, and a list of
knowledge gaps requiring future research studies. An evidence-todecision table is included for each CoSTR in Appendix A in the
Supplemental Materials.
The second major type of evidence evaluation performed to
support this 2020 CoSTR summary for PLS is a ScopRev.
ScopRevs are designed to identify the extent, range, and nature
of evidence on a topic or question, and they were performed by topic
experts in consultation with the PLS Task Force. The task force
analysed the identified evidence and determined its value and
implications for resuscitation practice or research. The rationale for
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the ScopRev, the summary of evidence, and task force insights—all
are highlighted in the body of this publication. Any previous
treatment recommendations are reiterated. The task force noted
whether the ScopRev identified substantive evidence that could
result in a change in the ILCOR treatment recommendations. If
sufficient evidence was identified, the task force suggested
consideration of a (future) SysRev to support the development of
an updated CoSTR. All ScopRevs are included in their entirety in
Appendix B in the Supplemental Materials.
The third type of evidence evaluation supporting this 2020
CoSTR for PLS is an EvUp. EvUps were generally performed to
identify new studies published after the most recent ILCOR
evidence evaluation, typically by using search terms and methodologies from previous reviews. These EvUps were performed by task
force members, collaborating experts, or members of council writing
groups. The EvUps are cited in the body of this publication with a
note as to whether the evidence suggested the need to consider a
SysRev; the most recent ILCOR treatment recommendation was
reiterated.
In this publication, no change in an ILCOR treatment recommendation resulted from a ScopRev or an EvUp; if substantial new
evidence was identified, the task force recommended consideration of
a SysRev. All EvUps are included in Appendix C in the Supplemental
Materials, as they were drafted by the reviewers.
Note: The reviews and treatment recommendations apply to
infants (28 days to 12 months) and children (the age definitions varied
in the cited studies). Evidence evaluation of studies of resuscitation of
newborns (especially at birth) can be found in “Neonatal Life Support:
2020 International Consensus on Cardiopulmonary Resuscitation
and Emergency Cardiovascular Care Science With Treatment
Recommendations”7a,7b in this supplement.

Topics Reviewed in This 2020 PLS CoSTR
Note: As indicated above, the PLS CoSTR evidence reviews were all
completed by January 10, 2020. As a result, this document does not
address the topic of potential influence of coronavirus disease 2019
(COVID-19) on resuscitation practice. In the spring of 2020, an ILCOR
writing group was assembled to identify and evaluate the published
evidence regarding risks of aerosol generation and infection
transmission during attempted resuscitation of adults, children, and
infants. This group developed a consensus on science with treatment
recommendations and task force insights. This statement is published
as a separate document.8 As new evidence emerges, the ILCOR task
forces will review and update this statement, so the reader is referred
to the ILCOR website7 for the most up-to-date recommendations.

Pediatric Basic Life Support (PBLS): CPR and CPR Quality

 Sequence of compression and ventilation (BLS 661: Shared
SysRev)
 Pulse check accuracy (PLS 393: EvUp)
 Chest compression only versus conventional CPR (2017
CoSTR)
 Pediatric compression depth (PLS 314: ScopRev)
 1-hand versus 2-hand compressions for children (PLS 375: EvUp)
combined with circumferential compressions for infants (PLS 416:
EvUp)

122
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[16_TD$IF]PBLS: Automated External Defibrillation

[17_TD$IF] Use of automated external defibrillators (AEDs) for infants with
out-of-hospital cardiac arrest (OHCA) (PLS 425: EvUp)
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 Energy doses for defibrillation (PLS 405: ScopRev)
 Single or stacked shocks for pediatric defibrillation (PLS 389:
EvUp)

[120_TD$IF]PALS: Airways, Oxygenation, and Ventilation

[16_TD$IF]PBLS: Prevention of Cardiac Arrest

[18_TD$IF] Pediatric early-warning scores (PEWS) (PLS 818: ScopRev)
 Pediatric medical emergency/rapid response teams (PLS 397:
EvUp)

[731_TD$IF]Pediatric Advanced Life Support (PALS): Recognition and
Treatment of Septic Shock

[19_TD$IF] Fluid administration for the child with septic shock (PLS 1534:
EvUp)
 Vasoactive drugs for septic shock (PLS 1604: ScopRev)
 Corticosteroids for pediatric septic shock (PLS 413: EvUp)

[123_TD$IF] Ventilation rate when a perfusing rhythm is present (PLS 3103A
and PLS 382: EvUp)
 Oxygen concentration during cardiac arrest (PLS 396: ScopRev)
 Ventilation during CPR with bag and mask compared with an
advanced airway (2019 CoSTR)
 Use of cuffed or uncuffed tracheal tubes (PLS 412: EvUp)
 Atropine for emergency intubation (PLS 821: EvUp)
 Cricoid pressure during intubation (PLS 376: EvUp)
 Use of devices to verify advanced airway placement (PLS 385:
EvUp)
 Ventilation rate with advanced airway during cardiac arrest (PLS
3103A and PLS 382: EvUp)

[120_TD$IF]PALS: Circulatory Support During CPR

[120_TD$IF]PALS: Recognition and Prearrest Treatments for Shock
[124_TD$IF] Extracorporeal CPR for in-hospital cardiac arrest (2019 CoSTR)
[19_TD$IF] Graded volume resuscitation for traumatic/haemorrhagic shock
(PLS 400: ScopRev)
 Timing of intubation for shock (PLS 399: EvUp)
 Prearrest care of the infant or child with dilated cardiomyopathy or
myocarditis (PLS 819: EvUp)
 Cardiogenic shock and inotropes (PLS 418: EvUp)

[120_TD$IF]PALS: Management of Deterioration With Pulmonary
Hypertension

[12_TD$IF] Prevention and management of pulmonary hypertensive crises in
infants and children (PLS 391: EvUp)
 Opioids, sedatives, and neuromuscular blocking drugs for
pulmonary hypertension (PLS New: EvUp)
 Therapy with inhaled nitric oxide or prostaglandin I2 for pulmonary
hypertensive crisis and right heart failure (PLS New: EvUp)

[120_TD$IF]PALS: Recognition and Treatment of Nonarrest Arrhythmias

[12_TD$IF]




Drugs for supraventricular tachycardia (PLS 379: EvUp)
Treatment for unstable ventricular tachycardia (PLS 409: EvUp)
CPR for heart rate of less than 60/min (PLS 1535: EvUp)
Drugs for the treatment of bradycardia: Atropine versus no
atropine and atropine versus epinephrine (PLS New: EvUp)
 Emergency transcutaneous pacing for bradycardia (PLS New:
EvUp)
 Channelopathies (PLS 417: EvUp)

[120_TD$IF]PALS: Physiological Monitoring During Arrest to Guide
Therapy and/or Intra-arrest Prognostication

[125_TD$IF] Invasive blood pressure monitoring during CPR (PLS 826:
ScopRev)
 Use of near-infrared spectroscopy (NIRS) during cardiac arrest
(PLS New: ScopRev)
 Bedside ultrasound to identify perfusing rhythm (PLS 408:
ScopRev)
 End-tidal CO2 monitoring during CPR (PLS 827: ScopRev)

[120_TD$IF]PALS: Resuscitation Drug Administration and Timing

[126_TD$IF] Methods of calculating pediatric drug doses (PLS 420: EvUp)
 Intraosseous (IO) versus intravenous (IV) route of drug administration (PLS, neonatal life support [NLS], and advanced life
support [ALS]: SysRev)
 Epinephrine time of initial dose and dose interval during CPR (PLS
1541: SysRev)
 Amiodarone versus lidocaine for shock-resistant ventricular
fibrillation or pulseless ventricular tachycardia (2018 CoSTR)
 Sodium bicarbonate administration for children in cardiac arrest
(PLS 388: EvUp)
 Calcium administration in children (PLS 421: EvUp)

[120_TD$IF]PALS: Special Resuscitation Situations—Septic Shock,
Congenital Heart Disease, and Trauma

[120_TD$IF]PALS: Manual Defibrillation

[17_TD$IF] Pad size, type, and placement for pediatric defibrillation (PLS 378
and PLS 043: EvUp)

[127_TD$IF] Resuscitation of the child with septic shock (PLS 1534: EvUp)
 Resuscitation of the patient with a single ventricle (PLS 390: EvUp)
 Resuscitation of the patient with hemi-Fontan or Fontan circulation
(PLS 392: EvUp)
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 Resuscitation after traumatic arrest (PLS 498: EvUp)

[120_TD$IF]PALS: Post-Cardiac Arrest Care, Including Postarrest
Prognostication
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Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
The confidence in effect estimates is so low that the panel decided
that a recommendation was too speculative.

Pulse Check Accuracy (PLS 393: EvUp)
[125_TD$IF] Targeted temperature management (2019 CoSTR)
 Oxygen and carbon dioxide targets in pediatric patients with return
of spontaneous circulation (ROSC) after cardiac arrest (PLS 815:
SysRev)
 Post-ROSC blood pressure control (PLS 820: EvUp)
 Post-ROSC neuro-prognostication and use of electroencephalogram (PLS 813 and PLS 822: EvUp)

PBLS: CPR and CPR Quality
The PBLS topics in this section include the optimal sequence of
compressions and ventilation, pulse check accuracy, compressiononly compared with conventional CPR, the optimal depth of chest
compressions, and 1-hand versus 2-hand chest compressions for
children and circumferential chest compressions for infants.

Sequence of Compression and Ventilation (BLS 661: Shared
SysRev)
The PLS Task Force last reviewed the sequence of pediatric BLS in
2015.9,10 In 2020, the BLS Task Force performed a SysRev on the
topic (see the Starting CPR section [BLS 661: SysRev] of the BLS
publication in this supplement). This SysRev search included adults
and children in all settings. Refer to the BLS publication for details of
the evidence summary and task force considerations.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults and children with OHCA
 Intervention: Commencing CPR beginning with compressions first
(30:2)
 Comparator: CPR beginning with ventilation first (2:30)
 Outcome: Survival with favourable neurological /functional
outcome at discharge, 30 days, 60 days, 180 days, and/or 1
year; survival only at discharge, 30 days, 60 days, 180 days, and/
or 1 year; and ROSC
 Study design: RCTs and nonrandomized studies (nonrandomized
controlled trials [non-RCTs], interrupted time series, controlled
before-and-after studies, cohort studies) eligible for inclusion
 Time frame: All languages were included if there was an English
abstract. The literature search was updated in September 2019.

Summary of Evidence
The 2020 PLS ScopRev did not identify any new human pediatric
evidence about sequencing for initiating CPR published after the 2015
CoSTR.11,12
As a result, the recommendations for sequencing of BLS steps for
infants and children in cardiac arrest remain unchanged from those
published in 2015 (see Treatment Recommendations), with insufficient evidence to make a recommendation. To review the entire
SysRev for adult data, see the Starting CPR section [BLS 661:
SysRev] of the BLS publication in this supplement.

This EvUp was performed to identify studies after the review about
pulse check accuracy in 2010.9,10 Studies about the accuracy of pulse
check versus assessment of signs of life were insufficient to identify
cardiac arrest, and the task force agreed that there is no need to
suggest consideration of a SysRev. As a result, the 2010 treatment
recommendation is unchanged.9,10 To review the EvUp, see [128_TD$IF]
Supplement Appendix C-1.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame





Population: Infants and children in cardiac arrest
Intervention: Use of pulse check
Comparator: Assessment of signs of life
Outcome: Improve accuracy of diagnosis of pediatric cardiopulmonary arrest
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and all languages were included if there was
an English abstract. Literature was updated in December 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
Palpation of a pulse (or its absence) is not reliable as the sole
determinant of cardiac arrest and need for chest compressions. If the
victim is unresponsive, and not breathing normally, and there are no
signs of life, lay rescuers should begin CPR.
In infants and children with no signs of life, healthcare providers
should begin CPR unless they can definitely palpate a pulse within 10
seconds.

Chest Compression-Only Versus Conventional CPR (2017
CoSTR)
In 2017, a SysRev13 and an ILCOR Pediatric CoSTR14,15 were
published on the topic of compression-only CPR compared with
conventional CPR for infants and children. Refer to those publications
for details of the evidence summary and task force considerations.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Patients of all ages (ie, neonates, children, adults) with
cardiac arrest from any cause and across all settings (in-hospital
and animals not eligible
 Intervention: All manual CPR methods including compressiononly CPR, continuous compression CPR, and CPR with different
compression-to-ventilation ratios. Compression-only CPR included continuous delivery of compressions with no ventilation;
continuous chest compression CPR included compression with
asynchronous ventilation or minimally interrupted cardiac resuscitation. Studies that mentioned the use of a mechanical device
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during CPR were considered only if the same device was used
across all relevant intervention arms and would therefore not
confound the observed effect.
Comparator: Studies had to compare at least 2 different CPR
methods from the eligible interventions; studies without a
comparator were excluded
Outcome: The primary outcome was favourable neurological
outcomes, evaluated by cerebral performance scale or a modified
Rankin Scale score; secondary outcomes were survival, ROSC,
and quality of life
Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion; study designs without a comparator
group (eg, case series, cross-sectional studies), reviews, and
pooled analyses excluded
Time frame: All years and languages were included if there was an
English abstract. The literature search was updated in December
2019.
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Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
Time frame: All years and languages were included if there was an
English abstract. The search was updated to October 2019.

Summary of Evidence
No new published evidence was identified with this ScopRev. The PLS
Task Force did identify an ongoing large prospective observational
international multicenter study on CPR quality using dual-sensor CPR
feedback devices: the pediRES-Q study.20 The results of this study,
once published, may help address the impact of chest compression
depth on CPR outcomes. The task force concluded that there is no
need to recommend a new SysRev at this time, and the decision will be
reconsidered following after the publication of any relevant studies.
For this 2020 CoSTR update, the 2015 treatment recommendations11,12 are unchanged.

Task Force Insights
Treatment Recommendations
These treatment recommendations are unchanged from 2017.14,15
We suggest that bystanders provide CPR with ventilation for
infants and children younger than 18 years with OHCA (weak
recommendation, very low-quality evidence). We continue to
recommend that if bystanders cannot provide rescue breaths as part
of CPR for infants and children younger than 18 years with OHCA, they
should at least provide chest compressions (good practice statement).

Pediatric Compression Depth (PLS 314: ScopRev)
Rationale for Review
The most recent (2015) PLS review11,12 about pediatric chest
compression depth was based on a SysRev that identified 2
observational pediatric studies.16,17 There is now greater availability
of CPR feedback devices providing real-time data about the specific
targets for components of CPR, including depth of compression;
studies in adults18,19 demonstrated that overcompression can cause
harm. The ScopRev was undertaken to determine the extent of current
available evidence about the effectiveness of various compression
depths used during resuscitation of infants and children. For details of
the ScopRev, see [128_TD$IF]Supplement Appendix B-1.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who had received chest
compressions after out-of-hospital or in-hospital cardiac arrest
(excluding newborn children)
 Intervention: Any specific chest compression depth
 Comparator: Depth specified in 2017 CoSTR publication14,15
At least one third the AP [anteroposterior] chest depth
Approximately 11/2 inches (4 cm) in infants, 2 inches (5 cm) in
children
 Outcome:
Short-term survival and neurological outcomes (eg, ROSC,
hospital discharge, 28 days, 30 days, and 1 month)
Long-term survival and neurological outcomes (eg, 3 months, 6
months, and 1 year)

The PLS Task Force recognized the paucity of pediatric studies and
substantial identified gaps in the pediatric literature about chest
compression depth (eg, the absence of data on the impact of
overcompression). Previous studies used feedback devices with a
single displacement sensor/accelerometer; these are notably unreliable because the compression depth they measure can be affected by
the type of surface on which the compressions are performed;
overestimation of compression depth occurs if the surface on which
the patient rests (eg, bed or trolley mattress) enables movement even
if a CPR board is used. Chest compression depth studies using
feedback devices with dual displacement sensors/accelerometers
may improve the accuracy of measurement of compression depth.

Treatment Recommendations
These treatment recommendations are unchanged from 2015.11,12
We suggest that rescuers compress an infant’s chest by at least
one third the anteroposterior dimension, or approximately 11/2 inches
(4 cm). We suggest that rescuers compress a child’s chest by at least
one third the anteroposterior dimension, or approximately 2 inches
(5 cm) (weak recommendation, very low-quality evidence).

One-Hand Versus 2-Hand Compressions for Children (PLS
375: EvUp) Combined With Circumferential Compressions
for Infants (PLS 416: EvUp)
An EvUp was performed to identify the available evidence about
different techniques for chest compressions of infants and children.
The previous review was published in 2010.9,10 The EvUp did identify
several studies published after 2010, and the task force agreed that
these studies suggest the need to consider requesting a SysRev. Until
a new SysRev is completed and [1069_TD$IF]analysed by the PLS Task Force, the
2010 treatment recommendation remains in effect. To review the
EvUp, see [128_TD$IF]Supplement Appendix C-2.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in cardiac arrest in any setting
 Intervention: 2 hands, 1 hand, circumferential, 2 fingers, a specific
other method, a specific location
 Comparator: Another method or location

RESUSCITATION 156 (2020) A120

 Outcome: Any
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. Literature was searched to December 2019.

Treatment Recommendation
This treatment recommendation (below) is unchanged from 2010.9,10
Either a 1-hand or a 2-hand technique can be used for performing
chest compressions on children.
There are insufficient data to make a recommendation for or
against the need for a circumferential squeeze of the chest when
performing the 2 thumb encircling hands technique of external chest
compression for infants.

PBLS: Automated External Defibrillation
Use of Automated External Defibrillators for Infants With Outof-Hospital Cardiac Arrest (PLS 425: EvUp)
An EvUp was performed to determine if there were any published
studies about the use of AEDs for infants with OHCA. The EvUp
identified insufficient evidence to justify a SysRev or suggest the need
for a change to the 2010 treatment recommendation; as a result, the
2010 treatment recommendation is unchanged.9,10 To review the
EvUp, see [128_TD$IF]Supplement Appendix C-3.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
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PBLS: Prevention of Cardiac Arrest
Pediatric Early-Warning Scores (PLS 818: ScopRev)
Rationale for Review
The topic was selected for review because the task force was aware of
several recent relevant publications, including SysRevs, a ScopRev,
and a large-scale RCT study published after the most recent (2015)
CoSTR on the topic.11,12
PEWS are tools that evaluate clinical presentation risk of clinical
deterioration or arrest.
See [128_TD$IF]Supplement Appendix B-2.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in a hospital setting
 Intervention: PEWS with or without rapid response teams/medical
emergency teams
 Comparator: No PEWS with or without rapid response teams or
medical emergency teams
 Outcome: In-hospital deterioration, including mortality
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract; unpublished studies (eg, conference abstracts,
trial protocols) were excluded. The literature search was updated
to September 15, 2019.

Summary of Evidence
 Population: Infants and children in cardiac arrest in any setting
 Intervention: Use of an automated external defibrillators at a
certain moment in the algorithm
 Comparator: At another moment in the algorithm or not using an
automated external defibrillator or using an automated external
defibrillator with a dose attenuator
 Outcome: Any
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. Literature was searched to December 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
For treatment of out-of-hospital ventricular fibrillation (VF)/
pulseless ventricular tachycardia (pVT) in infants, the recommended
method of shock delivery by device is listed in order of preference
below. If there is any delay in the availability of the preferred
device, the device that is available should be used. The AED
algorithm should have demonstrated high specificity and sensitivity for
detecting shockable rhythms in infants. The order of preference is as
follows:
1 Manual defibrillator
2 AED with dose attenuator
3 AED without dose attenuator

We identified 3 SysRevs21 23 and 1 ScopRev24 published after 2015;
all noted the limited evidence for the usefulness of PEWS for
preventing physiological deterioration and improving clinical
outcomes.
The Evaluating Processes of Care and the Outcomes of Children
in Hospital (EPOCH) study was published in 2018. This was an
international cluster RCT of 21 hospitals enrolling patients from birth
(gestational age 37 weeks or more) up to 18 years of age.25 This study
included all-cause mortality as a primary outcome, with a secondary
outcome a composite outcome reflecting late critical care admission.
Ten hospitals implemented a bedside PEWS system compared with
usual care (ie, did not use a severity early-warning score) in 11
hospitals. This was one of the largest studies of its kind, involving 144
539 patient discharges with 559 443 patient days and 144 539 patients
in total completing the trial.
There was no significant reduction in all-cause mortality when the
use of bedside PEWS was compared with standard care (1.93 per
1000 patient discharges compared with 1.56 per 1000 patient
discharges; adjusted odds ratio [OR], 1.01; 95% CI, 0.61 1.69).
The prevalence of significant clinical deterioration events was lower
(0.5 per 1000 patient days compared with 0.84 per 1000 patient days)
at hospitals using bedside PEWS compared with usual care hospitals
(adjusted rate ratio 0.77 [95% CI, 0.61 0.97]).
The EPOCH authors concluded that their findings did not support
the use of PEWS to reduce mortality but did support the use of bedside
PEWS to decrease clinically important deterioration on the wards in
nontertiary care/ and community hospitals.25
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The PLS draft ScopRev was posted on the ILCOR website and was
viewed 345 times without any comments that addressed the need for a
SysRev on this topic. To review the ScopRev, see [128_TD$IF]Supplement
Appendix B-2.

Task Force Insights
The PLS Task Force concluded that the implementation of PEWS
should be part of an overall clinical response system, with the task
force placing a higher value on improving healthcare provider ability
to recognize and intervene for patients with deteriorating illness over
the expense incurred by a healthcare system committing significant
resources to implement PEWS. The task force also noted that the
complex process of optimizing patient care is likely to include both
the implementation of PEWS and ongoing healthcare provider
education. The PLS Task Force agreed that the decision to use
PEWS should be balanced between use of existing resources and
capabilities of the healthcare setting to adapt to its use and the
consequences of its use.
In the PEWS studies, mortality is a common outcome marker.
However, the incidence of cardiac arrest is low (especially outside the
critical care setting), so the incidence of significant clinical deterioration is an additional important outcome in determining sample sizes for
such studies.
The PLS Task Force agreed that there is no need to request a
SysRev, and the 2015 treatment recommendations remain in
effect.11,12

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
The confidence in the estimate of predictive value is so low that the
panel decided that a recommendation is too speculative.11,12

Pediatric Medical Emergency/Rapid Response Teams (PLS
397: EvUp)
Rapid response teams (RRTs) are hospital teams that are activated to
evaluate and respond to patients at risk for clinical deterioration. The
topic of medical emergency teams (METs)/RRTs was last reviewed in
2015. This EvUp was requested to identify relevant evidence on the
topic published after that date.11,12 Two preintervention/postintervention studies demonstrated a decrease in the number of
resuscitation events, although there was no clear decrease in
mortality. One observational registry study demonstrated no change
in the mortality rate beyond that which was already expected from the
preimplementation trends. This finding is not significantly different
from the 2015 review. To review the EvUp, see [128_TD$IF]
Appendix CSupplement Appendix C-4. There is no indication to
change the 2015 CoSTR recommendation.

Treatment Recommendation
This treatment recommendation (below) is unchanged from 2015.11,12
We suggest the use of pediatric MET/RRT systems in hospitals
that care for children (weak recommendation, very low-quality
evidence). In making this recommendation, we place a higher value
on the potential to recognize and intervene for patients with
deteriorating illness over the expense incurred by a healthcare
system by committing significant resources to implement a MET/RRT
system. We recognize that the decision to use a MET/RRT system
should be balanced by the existing resources and capabilities of the
institution.
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PALS: Recognition and Treatment of Septic
Shock
Fluid Administration for the Child With Septic Shock (PLS
1534: EvUp)
Note: This topic was prioritized for review because the approach to the
management of fluid resuscitation in infants and children with septic
shock is changing as a result of recent published evidence. The
summary of this EvUp is more detailed than for other EvUps owing to
the critical nature of these new findings and in acknowledgment of the
2020 publication of new guidelines for the management of infants and
children with septic shock.26
This topic was last reviewed in 2015,11,12 when the evidence
evaluation included fluid administration for shock associated with
dengue fever and malaria. This EvUp looked specifically at the impact
of different fluid regimens in infants and children with septic shock but
excluded studies of shock associated with dengue or malaria because
the pathophysiology of shock with those conditions is atypical when
compared with septic shock associated with other causes. The role of
fluid administration in shock associated with dengue or malaria will be
considered in future EvUp work.
This draft EvUp can be viewed in [128_TD$IF]Supplement Appendix C-5
because it is only outlined here in the main body of text. It included 12
studies in the final evidence review: 3 RCTs27 29 and 3 SysRevs.30 32
In addition, the EvUp identified 1 RCT33 that did not directly address
the PICO (population, intervention, comparator, outcome) question
but provided information about the effect of a fluid bolus on cardiac
index. The EvUp also [1069_TD$IF]analysed the results of 4 nonrandomized
studies34 37 and 1 study protocol.38
The Society of Critical Care Medicine’s Surviving Sepsis
Campaign International Guidelines for the Management of Septic
Shock and Sepsis-Associated Organ Dysfunction in Children was
published in February 2020,26 immediately before the submission of
this publication. In these 2020 surviving sepsis guidelines, recommendations for fluid administration differ based on the availability of
intensive care within the system caring for the infant or child. For
systems with the availability of intensive care, the authors suggest the
administration of 10 to 20 mL/kg boluses, up to a total of 40 to 60 mL/kg
in the first hour, being titrated to the patient’s response and to be
discontinued if the signs of fluid overload develop. If hypotension is
present in systems without the availability of intensive care, the
authors suggest the administration of 10 to 20 mL/kg boluses, up to a
total of 40 mL/kg in the first hour (also titrated to response and
discontinued if signs of fluid overload develop). If the infant or child is
not hypotensive and is in a system without the availability of intensive
care, the authors recommend against bolus fluid administration but to
start maintenance fluids.26
The PLS Task Force agreed that a new SysRev is needed to
reevaluate the evidence and modify the 2015 PLS treatment
recommendations as needed. Until the SysRev is completed and [1069_TD$IF]
analysed by the task force, the 2015 treatment recommendations
remain in effect.11,12

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are in septic shock in any
setting
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 Intervention 1: Use of restrictive volume of resuscitation fluid (less
than 20 mL/kg)
 Comparator 1: Nonrestrictive volume (20 mL/kg or greater) or the
use of noncrystalloid fluids
 Intervention 2: Use of noncrystalloid fluids
 Comparator 2: Use of crystalloid fluids
 Intervention 3: Use of balanced crystalloid solution (eg, Ringer’s
lactate)
 Comparator 3: Use of unbalanced isotonic crystalloid solution
(normal saline)
 Outcome: Survival to hospital discharge, need for mechanical
ventilation, need for vasopressor support, complications, time to
resolution of shock, hospital length of stay, ventilator-free days, or
total IV fluids administered
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and all languages were included if there was
an English abstract. The literature search was from January 2015
to January 2020.

Treatment Recommendations
These treatment recommendations are unchanged from 2015.11,12
We suggest using an initial fluid bolus of 20 mL/kg for infants and
children with shock, with subsequent patient reassessment, for
patients with the following disease states:
 Severe sepsis (weak recommendation, low-quality evidence)
 Severe malaria (weak recommendation, low-quality evidence)*
 Dengue shock syndrome (weak recommendation, low-quality
evidence)*
We suggest against the routine use of bolus intravenous fluids
(crystalloids or colloids) for infants and children with a “severe febrile illness”
who are not in shock (weak recommendation, low-quality evidence).*
Reassessment, regardless of therapy administered, should be
emphasized so that deterioration is detected at an early stage.
*These populations were included in the 2015 CoSTR but not the
2020 EvUp.
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Intervention: Use of any specific vasoactive drug
Comparator: Standard care
Outcome: Improved patient outcomes (hemodynamics, survival)
Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was from 1946 to
November 2019.

Summary of Evidence
The ScopRev identified 2 relevant RCTs. The first39 included 60
children with septic shock in emergency departments or critical care
units and compared the effects of dopamine with those of epinephrine.
The primary outcome was resolution of shock in the first hour, which
was more likely to occur among those receiving epinephrine rather
than dopamine (OR, 4.8; 95% CI, 1.3 17.2; P = 0.019). On day 3,
there were lower sequential organ failure assessment scores (ie, less
derangement) in the epinephrine group (8 versus 12, P = 0.05). There
was no difference in the adverse event rate (16.1% versus 13.8%,
P = 0.8) and no difference in mortality, although this study was not
powered for mortality.
The second study40 was a double-blind RCT that evaluated 120
children with refractory septic shock (despite the administration of
40 mL/kg of fluid). Randomization was to either dopamine or
epinephrine, with the primary outcome of 28-day mortality and the
secondary outcome of healthcare-associated infection. Dopamine
administration was linked with an increased risk of death and
healthcare-associated infection in comparison with epinephrine
administration. The PLS Task Force members were concerned that
the doses of epinephrine would have produced a disproportionately
greater physiological effect than the matched doses of dopamine. To
review the ScopRev, see [128_TD$IF]Supplement Appendix B-4.
Of note, the 2020 surviving sepsis guidelines26 suggest the use of
epinephrine or norepinephrine compared with dopamine based on
very-low-quality evidence. The authors state that they could not make
a recommendation for a first-line vasoactive infusion for septic shock,
noting that in their practices they use epinephrine or norepinephrine.

Task Force Insights
Vasoactive Drugs for Septic Shock (PLS 1604: ScopRev)
Rationale for Review
Although pediatric septic shock is associated with significant mortality/
morbidity, substantial progress has been made in improving the
recognition of septic shock and the development of bundles of care
aimed at bettering patient outcomes. The most recent review of
vasoactive drugs (labeled “inotropes and vasopressors”) for septic
shock was published in 2010.9,10 That CoSTR considered all forms of
distributive shock, whereas this ScopRev looked specifically at the
use of vasoactive drugs in pediatric septic shock, excluding other
forms of distributive shock. This ScopRev looked at comparative
studies of 1 vasoactive drug with another. To review the ScopRev, see [128_TD$IF]
Supplement Appendix B-3.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with septic shock, with and
without myocardial dysfunction

The studies identified by the ScopRev did not evaluate vasoactive
agents other than dopamine and epinephrine and did not include other
drugs such as norepinephrine that are commonly used to treat fluidresistant septic shock. The 2 RCTs were single-center studies in lowand middle-income healthcare systems, so questions about their
generalizability to other healthcare settings arose. The task force
agreed that the adult findings could not be extrapolated to the pediatric
population because infants and children have different physiological
responses to vasoactive drugs (varying according to age even within
the age range of infants and children), particularly when compared
with adult physiological responses.
The task force agreed that the current evidence does not support
the need for a SysRev and the 2010 treatment recommendations
remain in effect.9,10

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
There is insufficient evidence to recommend a specific inotrope or
vasopressor to improve mortality in pediatric distributive shock. The
selection of an inotrope or vasopressor to improve hemodynamics
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should be tailored to each patient’s physiology and adjusted to the
individual’s clinical responses.

Corticosteroids for Pediatric Septic Shock (PLS 413: EvUp)
The PLS Task Force sought an EvUp on this topic because it was last
reviewed in 2010.9,10 The evidence for or against the use of
corticosteroids in pediatric septic shock is of very low certainty.
There is limited evidence that a specific subpopulation may benefit
from the administration of corticosteroids, but these patients are not
easily identifiable at the bedside. As a result, the current (2010)
treatment recommendation continues unmodified. To review the
EvUp, see [128_TD$IF]Supplement Appendix C-6.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children being treated for septic shock and
circulatory failure in any setting, during the first hours of treatment
 Intervention: Early administration of corticosteroids
 Comparator: No corticosteroid or postponed administration
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was conducted to
December 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
There is insufficient evidence to support or refute the routine use of
stress-dose or low-dose hydrocortisone and/or other corticosteroids
in infants and children with septic shock. Stress-dose corticosteroids
may be considered in children with septic shock unresponsive to fluids
and requiring vasoactive support.

PALS: Recognition and Prearrest Treatments
for Shock
Graded Volume Resuscitation for Traumatic/Hemorrhagic
Shock (PLS 400: ScopRev)
Rationale for Review
The PLS Task Force reevaluated this topic because the previous
review was published in 2010.9,10 This 2020 ScopRev sought to
identify available evidence about the effectiveness of graded volume
resuscitation compared with standard care for traumatic hemorrhagic
shock. To review the ScopRev, see [128_TD$IF]Supplement Appendix B-4.
The term graded volume resuscitation includes restrictive volume
resuscitation and permissive hypotension, with volume administered
to resuscitate a hypovolemic trauma victim with relatively small
volumes, repeated to restore perfusion to a specific target.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in hemorrhagic shock following
trauma in any setting
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 Intervention: Graded volume resuscitation (now restrictive volume
resuscitation)
 Comparator: Standard care
 Outcome: Any clinical outcome
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was from March 2009 to
November 2019.

Summary of Evidence
Six retrospective pediatric studies were identified.41 46 All were
derived from trauma registries. Only 1 study assessed the volume of
fluid given to children with traumatic injuries in the prehospital
setting.41 Four studies compared the total crystalloid volume given in
24 hours,42,44 46 and 1 study assessed the volume of crystalloid given
to patients needing transfusion.43 The study that reported the critical
outcome of survival to 24 hours41 found no benefit to survival
associated with graded/“limited” volume compared with standard care
for trauma resuscitation. None reported on survival at 30 days with
good neurological outcome. For the critical outcome of survival to
discharge, 4 studies found no benefit associated with graded/limited
volume administration compared with standard care.41,44,46,47 One
study reported lower survival to hospital discharge associated with
high-volume crystalloid administration (greater than 60 mL/kg per
24 hours) compared with low- and moderate-volume crystalloid
administration (ie, 0 40 mL/kg per 24 hours or 40 60 mL/kg per
24 hours),42 and 1 reported lower survival rates associated with higher
transfusion volumes (ie, greater than 50 mL/kg per 24 hours compared
with those receiving 150 mL/kg or less per 24 hours).43 Five studies
reported an increased hospital or intensive care length of stay
associated with higher crystalloid volume administration in the first
24 hours.42 44,46,47 All studies were retrospective, and they reported
different interventions on differing patient populations and differing
associated outcomes. Although it is difficult to compare results, there
is a suggestion of a possible advantage of using limited volume
resuscitation. To review the ScopRev, see [128_TD$IF]Supplement Appendix B-4.

Task Force Insights
The task force discussed the term graded resuscitation used in the
2010 CoSTR evidence evaluation; this term was infrequently found in
the trauma literature published in the past decade. The task force
discussed the definition of hypotensive resuscitation in children and
infants with trauma (because it was agreed that this is unclear in the
literature), as well as other terms used in trauma resuscitation, such as
restrictive resuscitation and delayed versus early resuscitation.
Adult data favor restrictive volume resuscitation, and the
recommendations for this population have been to promote damage
control resuscitation. The National Institute for Health and Care
Excellence trauma guidelines48 and the American College of
Surgeons Advanced Trauma Life Support guidelines49 follow these
principles for adult practice because both suggest restrictive volume
resuscitation with early use of blood components in hemorrhagic
shock.
The task force discussed the ILCOR mandate and whether it
includes the review and analysis of trauma resuscitation topics.
Because trauma remains a major cause of death in children worldwide
and there is still a lack of evidence-based guidelines, most task force
members agreed that this is an important issue for ILCOR to address.
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RCTs or, in their absence, studies from large trauma registries are
required to address the effects of different volume resuscitation
strategies on mortality and morbidity outcomes. Optimal timing for the
administration of fluid resuscitation in pediatric trauma was not
addressed in this review but will be considered for a future
SysRev.
The task force agreed that more data are needed, but this ScopRev
did not identify sufficient new evidence to prompt a new SysRev, so the
2010 treatment recommendation (noting insufficient evidence to
make a recommendation) remains in place.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
There is insufficient evidence about the best timing or quantity for
volume resuscitation in infants and children with hemorrhagic shock
following trauma.

Timing of Intubation for Shock (PLS 399: EvUp)
The evidence to support specific timing of intubation for infants and
children in shock (ie, all types of shock) was most recently evaluated in
2010.9,10 At that time, the PLS Task Force noted the paucity of
published evidence. This EvUp was undertaken to identify any
relevant evidence published thereafter. Once again, insufficient
evidence was identified to warrant the suggestion of a pediatric
SysRev as only 5 animal studies, one 1 adult study and the 2020
Society of Critical Care Medicine Surviving Sepsis Campaign
International Guidelines for the Management of Septic Shock and
Sepsis-Associated Organ Dysfunction in Children26 were identified.
The 2020 surviving sepsis guidelines authors noted they were “unable
to make a recommendation about whether to intubate children with
fluid-refractory-catecholamine-resistant septic shock. However, in our
practice, we commonly intubate children [with] fluid-refractorycatecholamine-resistant septic shock without respiratory failure.”26
To review the EvUp, see [128_TD$IF]Supplement Appendix C-7.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in shock
 Intervention: Early intubation and assisted ventilation
 Comparator: The use of these interventions only for respiratory
failure
 Outcome: Improved patient outcomes (hemodynamics, survival)
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to December
2019.
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Note: The 2020 surviving sepsis guidelines26 updated the
recommended therapy.

Prearrest Care of the Infant or Child With Dilated
Cardiomyopathy or Myocarditis (PLS 819: EvUp)
This EvUp was performed because the most recent PLS CoSTR on
the topic of prearrest care for a child with dilated cardiomyopathy or
myocarditis was in 2015.11,12 The management of these patients has
continued to evolve since then, noting that the EvUp identified an
additional 5 studies not captured in the 2015 CoSTR.
The task force agreed to consider a request for a SysRev to assess
those studies and any others identified pertaining to the prearrest care
of an infant or child with myocarditis. Until a new SysRev is completed
and [1069_TD$IF]analysed by the PLS Task Force, the 2015 treatment
recommendation (noting insufficient evidence to make a recommendation) remains in effect. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-8.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with myocarditis or dilated
cardiomyopathy and impending cardiac arrest
 Intervention: A specific approach
 Comparator: The usual management of shock or cardiac arrest
 Outcome: Survival with favourable neurological/functional outcome at discharge, 30 days, 60 days, 180 days, and/or 1 year;
survival to hospital discharge; cardiac arrest frequency; ROSC
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was completed in
September 2019.

Treatment Recommendation
This treatment recommendation (below) is unchanged from 2015.11,12
The confidence in effect estimates is so low that the panel decided
that a specific recommendation was too speculative.

Cardiogenic Shock and Inotropes (PLS 418: EvUp)
This EvUp was undertaken because the most recent CoSTR on the
topic was published in 2010,9,10 and the task force sought to identify
any studies published after that review. The task force agreed that
there is insufficient evidence identified in the EvUp to consider a
request for a SysRev. As a result, the 2010 treatment recommendations9,10 remain in place. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-9.

Treatment Recommendation
This treatment recommendation (below) is unchanged from 2010.9,10
The optimal timing for intubation of children in shock remains
unclear, although reports of children with septic shock suggested
potential beneficial effects of early intubation (before signs of
respiratory failure develop) combined with a protocol-driven management approach. When children in septic shock were treated with a
protocol that included therapy directed to normalizing central venous
oxygen saturation, patient outcome appeared to improve.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are being treated for
cardiogenic shock in any setting, during the first hours of treatment
 Intervention: The early addition of certain vasoactive drugs
 Comparator: Postponed administration and/or a specific vasoactive drug versus another
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 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to December
2019.
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 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.

Treatment Recommendations
Treatment Recommendations
This treatment recommendation (below) is unchanged from
2010.9,10
The catecholamine dose for inotropic support in cardiogenic
shock must be titrated for each individual because there is wide
variability in the clinical response to vasoactive drugs. It is
reasonable to use epinephrine, levosimendan, dopamine, or
dobutamine for inotropic support in infants and children with
cardiogenic shock. Milrinone may be beneficial for the prevention
and treatment of low cardiac output following cardiac surgery. There
are insufficient data to support or refute the use of norepinephrine in
pediatric cardiogenic shock.9,10

PALS: Management of Deterioration With
Pulmonary Hypertension
This section includes 3 topics about the management and prevention
of critical pulmonary hypertension crises in the infant or child. All were
evaluated by EvUps to identify the availability of evidence published
after the most recent review of the management of infants and children
with pulmonary hypertension (appeared in the literature in 2010).9,10

Prevention and Management of Postoperative Pulmonary
Hypertensive Crises in Infants and Children (PLS 391: EvUp)
Although the general topic of pulmonary hypertension was reviewed in
the 2010 CoSTR,9,10 the focus was on treatment of cardiac arrest in
patients with pulmonary hypertension. This EvUp was performed to
identify any evidence about the postoperative care of infants and
children with pulmonary hypertension at high risk of pulmonary
hypertensive crisis. The EvUp identified several RCTs. In addition, the
PLS Task Force is aware of 2 guidelines publications—1 from the
American Heart Association (AHA)[129_TD$IF]50,51 and 1 from the European
Pediatric Pulmonary Vascular Disease Network[130_TD$IF]51,51a —each group
having completed a SysRev in 2015. The task force agreed that the
EvUp identified sufficient published evidence to indicate the need to
consider a SysRev. Until such time as a new SysRev is completed and [1069_TD$IF]
analysed by the PLS Task Force, the 2010 treatment recommendation
remains in effect for treatment of children with pulmonary hypertension and cardiac arrest. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-10.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with pulmonary hypertension at
high risk of postoperative pulmonary hypertensive crises
 Intervention: Postoperative care such as careful respiratory
management and monitoring to avoid hypoxia and acidosis
 Comparator: Standard postoperative care
 Outcome: All

This treatment recommendation for the care of children with
pulmonary hypertension and cardiac arrest (below) is unchanged
from 2010.9,10
Rescuers should provide conventional PALS, including oxygenation and ventilation, for cardiac arrest associated with pulmonary
hypertension. It may be beneficial to attempt to correct hypercarbia. If
the administration of medications (IV or inhaled) to decrease
pulmonary artery pressure has been interrupted, it may be advisable
to reinstitute it.
Inhaled nitric oxide or aerosolized prostacyclin or analogues to
reduce pulmonary vascular resistance should be considered. If these
are unavailable, an IV bolus of prostacyclin may be considered.
Note: A SysRev will be needed to generate treatment recommendations for postoperative care of children with pulmonary
hypertension at risk for pulmonary hypertensive crisis.

Opioids, Sedatives, and Neuromuscular Blocking Drugs for
Pulmonary Hypertension (PLS New: EvUp)
Although the general topic of pulmonary hypertension was reviewed in
the 2010 CoSTR,9,10 the focus was on treatment during cardiac arrest;
there were no specific PICOST questions and no treatment
recommendations about the use of opioids, sedatives, and neuromuscular blocking drugs for an infant or a child with pulmonary
hypertension who is not in cardiac arrest. The EvUp identified 2
guidelines publications—one 1 from the AHA[129_TD$IF]50,51 and 1 from the
European Pediatric Pulmonary Vascular Disease Network[130_TD$IF]51,51a—
each group having completed a SysRev in 2015. To review the EvUp,
see [128_TD$IF]Supplement Appendix C-11. The PLS Task Force agreed to
consider the need for a SysRev to evaluate the available evidence and
see if treatment recommendations were required after review of the
literature.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children at high risk of pulmonary
hypertensive crises
 Intervention: Provision of adequate opiates, sedatives, and
neuromuscular blocking drugs
 Comparator: Standard care without opiates
 Outcome: All, especially pulmonary hypertensive crises
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.

Treatment Recommendations
There are no previous treatment recommendations.
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Therapy With Inhaled Nitric Oxide or Prostaglandin I2 for
Pulmonary Hypertensive Crisis and Right Heart Failure (PLS
New: EvUp)
Although the general topic of pulmonary hypertension was reviewed in
the 2010 CoSTR,9,10 the focus was on the treatment of cardiac arrest;
this 2020 EvUp focused on the evidence supporting inhaled nitric
oxide or prostaglandin I2 to manage pulmonary hypertensive crises
and right heart failure in infants and children with or without cardiac
arrest. This EvUp identified 2 guidelines publications—1 from the
AHA50 and 1 from the European Pediatric Pulmonary Vascular
Disease Network51 —each group having completed a SysRev in 2015.
In addition, a previous EvUp (see [128_TD$IF]Supplement Appendix C-12)
identified a SysRev52 that reported the results of an RCT on inhaled
nitric oxide for the postoperative treatment of pulmonary hypertension.53 See Supplement Appendix C-12.
The EvUp and the PLS Task Force member group identified
sufficient published data about the use of inhaled nitric oxide and
prostaglandin I2 to consider recommending a SysRev to evaluate the
available evidence and, if required, make new treatment recommendations. Until a new SysRev is completed and [1069_TD$IF]analysed, the 2010
treatment recommendations remain in effect for the general
management of pulmonary hypertension and not specifically to
address this PICOST because that will require further analysis of the
literature.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame









Population: Infants and children at high risk of pulmonary
hypertensive crises
Intervention: Provision of pulmonary vasodilators such as inhaled
nitric oxide or prostaglandin I2
Comparator: Standard therapy with no provision of therapy such
as inhaled nitric oxide or prostaglandin I2
Outcome: Alter the outcome of pulmonary hypertensive crises or
acute right heart failure
Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.
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PALS: Recognition and Treatment of Nonarrest
Arrhythmias
Drugs for Supraventricular Tachycardia (PLS 379: EvUp)
This topic was last reviewed in 2010.9,10 This EvUp was to identify any
evidence about the management of supraventricular tachycardia in
infants and children published after 2010. The EvUp identified 6 studies;
all were retrospective and observational, and none compared
adenosine with other IV drugs for the management and resolution of
supraventricular tachycardia. The PLS Task Force concluded that there
was insufficient evidence to suggest the need for a SysRev and no need
to consider a change in the previous (2010) treatment recommendations.9,10 To review the EvUp, see [128_TD$IF]Supplement Appendix C-13.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with supraventricular tachycardia
with a pulse
 Intervention: Use of any drug or combination of drugs
 Comparator: Adenosine
 Outcome: Termination of abnormal rhythm, survival
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract from ILCOR 2010 guidance. The search was
performed in November 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
For infants and children with supraventricular tachycardia with a
palpable pulse, adenosine should be considered the preferred
medication. Verapamil may be considered an alternative therapy in
older children, but it should not be routinely used in infants.
Procainamide or amiodarone given by a slow IV infusion with careful
hemodynamic monitoring may be considered for refractory supraventricular tachycardia.
Note: The 2020 PLS Task Force wishes to add the caveat that
expert consultation is encouraged before the use of procainamide or
amiodarone.

Drugs for Unstable Tachycardia (PLS 409: EvUp)
Treatment Recommendations
The broad treatment recommendations published in 2010, including
regarding inhaled nitric oxide, remain in effect.9,10
Rescuers should provide conventional PALS, including oxygenation and ventilation for cardiac arrests associated with pulmonary
hypertension. It may be beneficial to attempt to correct hypercarbia. If
the administration of medications (IV or inhaled) to decrease
pulmonary artery pressure has been interrupted, it may be advisable
to reinstitute it.
Inhaled nitrous oxide or aerosolized prostacyclin or
analogue to reduce pulmonary vascular resistance should be
considered. If unavailable, an IV bolus of prostacyclin may be
considered.9,10

The management of unstable VT was last reviewed in 2010.9,10 This
2020 EvUp was to determine if there was sufficient evidence to
consider a SysRev. The task force concluded that there was
insufficient published evidence of the management of unstable
tachycardia to recommend the consideration of a SysRev, so the 2010
treatment recommendations remain in effect.9,10 To review the EvUp,
see [128_TD$IF]Supplement Appendix C-14.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with unstable ventricular
tachycardia (prehospital and in-hospital)
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 Intervention: Any drug, combination of drugs, or intervention (eg,
cardioversion)
 Comparator: No drugs or intervention
 Outcome: Termination of rhythm, survival
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The search was finished in November 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
It is reasonable to use synchronized electric cardioversion as the
preferred first therapy for pediatric VT with hypotension or evidence of
poor perfusion. If drug therapy is used to treat unstable VT,
amiodarone may be a reasonable choice, with careful hemodynamic
monitoring performed during its slow delivery.

CPR for Heart Rate of Less Than 60/min (PLS 1535: EvUp)
PLS council guidelines54,55 recommend that PLS providers begin
chest compressions if an infant or child has a heart rate under 60
beats per minute with signs of poor perfusion despite support of the
airway, adequate oxygenation, and ventilation; this recommendation represents expert consensus provided by council guidelines
rather than by an ILCOR evidence review. No previous search
strategy was identified for this topic. As a result, a new search
strategy was developed. The EvUp identified 2 nonrandomized
studies that documented improved outcomes associated with CPR
for bradycardia with pulses and poor perfusion when compared with
outcomes associated with pulseless electric activity or asystole
cardiac arrest without preceding chest compressions.56,57 Lower
survival was associated with longer time intervals between the start
of CPR for bradycardia with pulse and poor perfusion, and the loss
of the pulse.56
Although the evidence base is limited, the task force agreed that
the importance of the question when to initiate CPR for bradycardia
suggests the need for consideration of a SysRev. To review the EvUp,
see [128_TD$IF]Supplement Appendix C-15.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are in cardiac arrest
 Intervention: Starting CPR if they have a heart rate of less than 60/
min with signs of shock and with a palpable pulse
 Comparator: Starting CPR for patients with a heart rate of less than
60/min and no palpable pulse
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion; unpublished studies (eg, conference
abstracts, trial protocols) excluded
 Time frame: All years since 2010 and all languages were included
if there was an English abstract until December 2019.

Treatment Recommendations
There is no ILCOR PLS treatment recommendation at this time.
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Drugs for the Treatment of Bradycardia: Atropine Versus No
Atropine and Atropine Versus Epinephrine (PLS 2 New:
EvUps)
The PLS Task Force reviewed this topic in 2010.9,10 Two EvUps were
performed to determine if any studies were published after 2010 about
atropine compared with epinephrine (see [128_TD$IF]Supplement Appendix C16) and atropine compared with no atropine (see Supplement
Appendix C-17) for the treatment of bradycardia in infants or children.
The EvUps identified no studies published after 2010. After
completion of the reviews, however, the task force identified 1
nonrandomized (in-hospital registry) study about epinephrine for
children receiving CPR for bradycardia and poor perfusion.58 The PLS
Task Force agreed that there remains insufficient evidence for
consideration of a SysRev; as a result, the 2010 treatment
recommendation remains in effect.9,10

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with bradycardia for any reason
 Intervention: Use of atropine at a specific dose
 Comparator: Not using atropine, using another drug, or using it
[atropine] at a different dose
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was conducted in
November 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from
2010.9,10
Epinephrine may be administered to infants and children with
bradycardia and poor perfusion that is unresponsive to ventilation and
oxygenation. It is reasonable to administer atropine for bradycardia
caused by increased vagal tone or anti-cholinergic drug toxicity. There
is insufficient evidence to support or refute the routine use of atropine
for pediatric cardiac arrest.

Emergency Transcutaneous Pacing for Bradycardia (PLS
New: EvUp)
This topic was last addressed by the Pediatric Task Force in 2000,59
when an international consensus on science and international
guidelines were published. As a result, the PLS Task Force requested
an EvUp to determine if there was relevant evidence to suggest the
need to consider a SysRev. After review of the EvUp (see [128_TD$IF]Supplement
Appendix C-17), the task force agreed that there is insufficient
evidence to suggest the need for a SysRev. As a result, the 2000
treatment recommendation remains in effect.59

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
There was no previous PICOST for this question. See [128_TD$IF]Supplement
Appendix C-18 for details of the search strategy.
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Treatment Recommendations
This treatment recommendation (below) is unchanged from 2000.59
In selected cases of bradycardia caused by complete heart block
or abnormal function of the sinus node, emergency transthoracic
pacing may be lifesaving. Pacing is not helpful in children with
bradycardia secondary to a postarrest hypoxic/ischemic myocardial
insult or respiratory failure. Pacing was not shown to be effective in the
treatment of asystole in children.

Channelopathies (PLS 417: EvUp)
The topic of channelopathies was last addressed in the PLS 2010
CoSTR.9,10 That review as well as this 2020 EvUp considered a
channelopathy after either sudden, unexplained death in children or
after an attempted resuscitation following sudden unexplained
cardiac arrest in a previously healthy child or young adult.
One issue identified in both the 2010 and this 2020 evidence
evaluation is that there is a role for selective screening for inheritable
heart disease and channelopathy where indicated but that expert
advice should be sought in this regard. To review the EvUp see [128_TD$IF]
Supplement Appendix C-19. The 2010 treatment recommendation
remains in effect.9,10 For clarity, the task force modified the first
sentence to begin with “Following attempted resuscitation for” before
“sudden cardiac arrest” to make clear that the screening is performed
after resuscitation efforts, not during them.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
The following PICOST elements were used in the 2010 review.9,10
 Population: Infants and children undergoing resuscitation from
cardiac arrest
 Intervention: Consideration of a channelopathy as the etiology of
the cardiac arrest
 Comparator: Standard management
 Outcome: ROSC, survival to discharge, survival with favourable
neurological outcome
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract in ILCOR. The search was performed in
November 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
After attempted resuscitation for sudden unexplained cardiac
arrest, providers should obtain a thorough history (including
syncopal episodes, seizures, unexplained accidents/or drownings, or sudden death) and review any available previous
electrocardiograms. All infants, children, and young adults with
sudden, unexpected death should, if possible, have an unrestricted complete autopsy, preferably performed by pathologists with
training and expertise in cardiovascular pathology. Consideration
should be given to the reservation and genetic analysis of tissue
from the index patient to determine the presence or absence of a
channelopathy. It is recommended that families of patients who
child’s cause of death is not found on autopsy be referred to a
healthcare provider or center with expertise in cardiac rhythm
disturbances.9,10

PALS: Manual Defibrillation
This section includes several topics on the subject of pediatric manual
defibrillation, including pad size and type and pad or paddle placement
during defibrillation, the use of stacked shocks, and the evidence
about defibrillation energy dose in infants and children.

Pad Size, Type, and Placement for Pediatric Defibrillation
(PLS 378 and PLS 043: EvUp)
The topics of pad size and placement and adhesive pads compared
with paddles were last reviewed in 2010.9,10 In the decade after that
review, the technological advances were rapid, hence an EvUp was
performed to identify any relevant evidence published after 2010. The
PLS Task Force agreed to combine these topics into a single EvUp
because they expected to identify relatively little evidence. (To review
the EvUp, see [128_TD$IF]Supplement Appendix C-20). The task force agreed
that the EvUp did not identify sufficient evidence to suggest the need to
consider a SysRev, so the 2010 treatment recommendations for both
topics remain in effect.9,10

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in cardiac arrest in any setting
 Intervention: Specific use of self-adhesive pads or any specific
paddle or pad size, orientation, and position
 Comparator: Use of paddlesor any other paddle or pad size,
orientation, and position
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was from 2010 to
December 2019.

Treatment Recommendations
These treatment recommendations are unchanged from 2010.9,10
There is insufficient evidence to alter the current recommendations
to use the largest size paddles that fit an infant’s or child’s chest
without touching each other or to recommend one paddle or pad
position or type over another.
Either self-adhesive defibrillation pads or paddles may be used in
infants and children in cardiac arrest.

Energy Doses for Defibrillation (PLS 405: ScopRev)
Rationale for Review
In the 2015 CoSTR,11,12 the PLS Task Force recommended an initial
dose of 2 to 4 J/kg to treat shockable rhythms of cardiac arrest. There
are differences in the first shock dose recommended by ILCOR
member councils, however, with the European Resuscitation Council
recommending 4 J/kg for the first and all subsequent shocks55 and the
AHA recommending an initial dose of 2 to 4 J/kg (but for ease of
teaching, a dose of 2 J/kg is used in algorithms and training materials).
For refractory VF, the AHA guidelines recommend increasing the
defibrillation dose to 4 J/kg, suggesting that subsequent energy doses
should be at least 4 J/kg and noting that higher levels may be
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considered, not to exceed 10 J/kg.60 The task force undertook this
review to determine if sufficient evidence exists to recommend
consideration of a SysRev that may result in greater consistency in
doses recommended for pediatric manual defibrillation. See [128_TD$IF]
Supplement Appendix B-5.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are in VF or pVT in any setting
 Intervention: Specific energy dose or regimen of energy doses for
the initial or subsequent defibrillation attempt(s)
 Comparator: 2 to 4 J/kg
 Outcome: Harm to the patient, ROSC, hospital discharge, longterm survival, survival with good neurological outcome

Summary of Evidence
The review identified a single 2019 SysRev61 of pediatric human and
animal studies that met the search criteria. The SysRev identified no
studies linking the initial or cumulative energy delivered to survival to
hospital discharge and no link between long-term survival or survival
with good neurological outcome. Meta-analysis could not be
performed because the component population groups were extremely
heterogeneous.
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conclusions before submission of this PLS CoSTR, but the task force
did want to acknowledge this additional new publication.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
We suggest the routine use of an initial dose of 2 to 4 J/kg of
monophasic or biphasic defibrillation waveforms for infants or
children in VF or pVT cardiac arrest (weak recommendation, verylow-quality evidence). There is insufficient evidence on which to
base a recommendation for second and subsequent defibrillation
doses.11,12

Single or Stacked Shocks for Pediatric Defibrillation (PLS
389: EvUp)
The evaluation of the evidence in support of single compared with
stacked shocks for pediatric defibrillation was most recently
addressed in 2010.9,10 The task force undertook this EvUp to identify
any new evidence published after 2010. The task force agreed that
there was no new evidence to suggest the need to consider a request
for a SysRev or to change the 2010 treatment recommendation. To
review the EvUp, see [128_TD$IF]Supplement Appendix C-21.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame

Task Force Insights
Shockable rhythms are less common in infants and children with
OHCA (less than 10%62,63) compared with in-hospital cardiac arrest
(IHCA) (5% to 24%64,65) and lower in pediatric than in adult OHCA,66
as in IHCA cases.64 The task force acknowledged that the lower
frequency of occurrence does affect the sample size for studies to
demonstrate statistically significant improvement in survival associated with different defibrillation energy doses.
It may be difficult to determine accurately the precise weight of
children with OHCA in the prehospital arena (as may be the case in the
emergency department setting for such patients), hence the
calculation of defibrillation doses administered in J/kg could be
imprecise. In addition, the interval from cardiac arrest to the delivery of
first shock and the quality of CPR could each influence the outcomes
for VF or pVT survival after shock delivery.
None of the studies identified in the single SysRev61 found a
significant association between the initial defibrillation energy dose
and the rate of sustained ROSC or survival. The task force agreed that
this ScopRev did not identify sufficient new evidence to justify
consideration of a SysRev, so the 2015 treatment recommendation
remains in effect.11,12
Note: In June 2020, task force members received a PubMed
automated alert about the publication of a new study of energy doses
for pediatric defibrillation. The task force chair (IM) repeated the
original search and verified that the study identified67 was the only
study meeting the search criteria published since the November 2019
search on the topic. The new in-hospital registry study identified 422
infants and children 18 years of age or younger with cardiac arrest and
initial VF/pVT. First shock energy doses other than 1.7 to 2.5 J/kg were
associated with lower survival to hospital discharge among the 301
patients 12 years of age or younger with initial VF/pVT, and first shock
doses more than 2.5 J/kg were associated with lower survival rates in
all patients 18 years of age or younger with initial VF.67 There was
insufficient time for the task force to analyze the study or its

 Population: Infants and children in VF or pVT in any setting
 Intervention: More than 1 shock for the initial or subsequent
defibrillation attempt(s)
 Comparator: A single shock
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated in December
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
A single-shock strategy followed by immediate CPR (beginning
with chest compressions) is recommended for children with out-ofhospital or in-hospital VF or pVT.

PALS: Airways, Oxygenation, and Ventilation
Central to the management of the critically ill or injured child is to
ensure that the airway is patent and that ventilation and oxygenation
are effective.
In this section, the evidence evaluations for the following airway
and oxygenation and ventilation topics are summarized: ventilation
rate when a perfusing rhythm is present, oxygen concentration
during cardiac arrest, ventilation during CPR with bag and mask
compared with an advanced airway, use of cuffed or uncuffed
tracheal tubes, minute ventilation during cardiac arrest, use of
cricoid pressure during intubation, use of devices to verify advanced
airway placement, and ventilation rate with an advanced airway
during cardiac arrest.
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Ventilation Rate When a Perfusing Rhythm Is Present (PLS
31030A and PLS 382: EvUp)
This EvUp was undertaken to determine if there was published
evidence to support the recommendation to deliver 1 breath every 3
seconds or any other specific ventilation rate for infants and children
who require bag-mask ventilation but have a pulse and perfusing
rhythm. The 2000 CoSTR on pediatric basic life support noted, “the
goal of ventilation with a bag and mask should be to approximate
normal ventilation and achieve physiological oxygen and carbon
dioxide concentration while minimizing risk of iatrogenic injury.”68
(pI254)
The recommendation was based on expert consensus rather
than a formal review of the evidence on the subject. To review the
EvUp, see [128_TD$IF]Supplement Appendix C-22.
The PLS Task Force has not made any previous recommendations for specific ventilation rate for the infant or child with respiratory
arrest and a perfusing rhythm. Such recommendations have been
included in council guidelines rather than in the ILCOR CoSTRs. The
search conducted in December 2019 for this EvUp did not reveal any
relevant evidence, and the task force concluded that there was no
need to consider a recommendation for a SysRev.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with a perfusing rhythm but
absent or inadequate respiratory effort
 Intervention: Giving 1 breath every 3 to 5 seconds (12 20 breaths/
min)
 Comparator: Alternative ventilation rates
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated in February
2019.

Treatment Recommendations
No treatment recommendations will be made until a future SysRev
identifies sufficient evidence to make a recommendation.

Oxygen Concentration During Cardiac Arrest (PLS 396:
ScopRev)
Rationale for Review
The published evidence supporting a specific inspired oxygen
concentration to use during attempted resuscitation of infants and
children was last reviewed in 2010.9,10 To review the ScopRev, see [128_TD$IF]
Supplement Appendix B-6.
The evidence supporting titration of oxygen after ROSC is
addressed in a separate review; see Oxygen and Carbon Dioxide
Targets in Pediatric Patients With Return of Spontaneous Circulation
After Cardiac Arrest.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants (age 28 days to 12 months) and children in
cardiac arrest in any setting
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 Intervention: Fraction of inspired oxygen (FiO2) titrated to
oxygenation during cardiac arrest
 Comparator: Use of 100% oxygen (FiO2 1.00)
 Outcome: Any
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to October 2019.

Summary of Evidence
The ScopRev identified no available human studies in infants (beyond
the neonatal period) and children about oxygen concentration or its
titration during cardiopulmonary resuscitation. The ScopRev did
identify 2 SysRevs69,70 and a 2019 ILCOR CoSTR summary
statement71,72 about initial resuscitation of newborns, although these
were not relevant to this 2020 ScopRev. This is because they
pertained to the resuscitation of newborns in the first minutes of life (ie,
during the transition from placental to pulmonary oxygenation).
The ScopRev did identify 2 studies in immature animal
models,73,74 a SysRev with meta-analysis of neonatal animal
models,75 77 and 2 mature animal studies.78,79 From this body of
work, there appeared to be no difference among ROSC rates, but
greater evidence of metabolic derangement associated with the
administration of 100% oxygen during resuscitation of the animals.

Task Force Insights
There were no human studies in infants or children that addressed the
topic, and the indirectness of results from animal models were
considered insufficient to alter the existing 20109,10 treatment
recommendation. Also see Oxygen and Carbon Dioxide Targets in
Pediatric Patients With Return of Spontaneous Circulation After
Cardiac Arrest below.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.
Note that the task force deleted a second recommendation that was
included in the 2010 treatment recommendations regarding FIO2 after
ROSC because it is addressed in a separate 2020 treatment
recommendation.9,10
There is insufficient information to recommend a specific inspired
oxygen concentration for ventilation during attempted resuscitation
after cardiac arrest in infants and children.

Ventilation During CPR With Bag and Mask Compared With
an Advanced Airway (2019 CoSTR)
A 2019 SysRev80 and an ILCOR Pediatric CoSTR statement were
published as part of the 2019 CoSTR summary.71,72 The publications
addressed advanced airway interventions for pediatric cardiac arrest,
comparing bag-mask ventilation with ventilation by an advanced
airway. Refer to those publications for details of the evidence
summary and task force considerations.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in any setting (in-hospital or outof-hospital) who have received chest compressions or a shock and
are receiving CPR
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 Intervention: Placement of an advanced airway device
 Comparator: Primary—bag-mask ventilation alone or with non
advanced airway interventions; secondary—another advanced
airway device
 Outcome: Any clinical outcome
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to January
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2019, with
the minor addition of “or insertion of” before “a supraglottic
airway.”71,72
We suggest the use of bag-mask ventilation rather than tracheal
intubation or insertion of a supraglottic airway in the management of
children with cardiac arrest in the out-of-hospital setting (weak
recommendation, very-low–certainty evidence).
There is insufficient evidence to support any recommendation
about the use of tracheal intubation or insertion of a supraglottic airway
in the management of children with cardiac arrest in the in-hospital
setting.

Use of Cuffed or Uncuffed Tracheal Tubes (PLS 412:
EvUp)
The PLS Task Force last reviewed the evidence comparing cuffed with
uncuffed tracheal tubes in 2010.9,10 This 2020 EvUp was to identify
any evidence on the topic published after 2010. The EvUp identified 3
SysRevs, 2 RCTs, and 3 observational studies published since the
previous evidence review. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-23. The task force agreed that the evidence identified by
the 2020 EvUp supports the consideration of a SysRev about the use
of cuffed versus uncuffed tubes in cardiopulmonary resuscitation to
ascertain if the treatment recommendation requires modification. Until
the completion and analysis of a new SysRev, the 2010 treatment
recommendation remains in effect.9,10

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with respiratory failure who
undergo endotracheal intubation in any setting
 Intervention: Use of cuffed tracheal tubes
 Comparator: Use of uncuffed tracheal tubes
 Outcome: Any
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to December
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
Both cuffed and uncuffed tracheal tubes are acceptable for infants
and children undergoing emergency intubation. If tracheal tubes are
used, avoid excessive cuff pressures.
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Atropine for Emergency Intubation (PLS 821: EvUp)
The PLS Task Force reviewed the evidence about the routine use of
atropine as a premedication before emergency intubation in 2015.11,12
An EvUp was undertaken but found insufficient literature for
consideration of a SysRev. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-24. The 2015 CoSTR remains in effect.11,12

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children requiring emergency tracheal
intubation
 Intervention: Use of atropine as a premedication before intubation
 Comparator: No use of atropine
 Outcome: Survival with favourable neurological outcome at 180
days, survival to hospital discharge, survival with favourable
neurological outcome at 30 days follow-up, survival with
favourable neurological outcome at discharge, likelihood of
cardiac arrest, likelihood of shock, incidence of arrhythmias
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
Englishabstract.TheliteraturesearchwasupdatedtoSeptember 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
The confidence in effect estimates is so low that the panel decided
that a recommendation was too speculative.

Cricoid Pressure During Intubation (PLS 376: EvUp)
The PLS Task Force last reviewed the evidence about the use of
cricoid pressure during tracheal intubation in 2010.9,10
The EvUp identified 2 observational studies suggesting an
association between external laryngeal manipulation, such as cricoid
pressure, and increased difficulty during tracheal intubation of children
in the emergency setting. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-25. The PLS Task Force concluded that they should
consider the need for a comprehensive SysRev to determine if the
2020 treatment recommendation should be amended. Until a new
SysRev is completed and [1069_TD$IF]analysed by the PLS Task Force, the 2010
treatment recommendation remains in effect.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children treated for acute illness or injury in
any setting, during first hour of treatment
 Intervention: Use of cricoid pressure or laryngeal manipulation
during endotracheal intubation
 Comparator: Any other type of or no laryngeal manipulation
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to December
2019.
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Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
If cricoid pressure is used during emergency intubation in infants
and children, it should be discontinued if it impedes ventilation or
interferes with the speed or ease of intubation.

Use of Devices to Verify Advanced Airway Placement (PLS
385: EvUp)
This 2020 EvUp was undertaken to determine if there was new
evidence to support the use of devices to confirm advanced airway
placement published after the most recent review of the topic in
2005.81 The EvUp identified 1 SysRev,82 relevant output from national
surveys,83 and 3 RCTs.84,85 Although these studies chiefly involved
adults or preterm infants rather than infants beyond 28 days of age or
children, the PLS Task Force agreed that there is sufficient new
evidence to suggest the need to consider a SysRev. Until a new
SysRev is completed and [1069_TD$IF]analysed by the PLS Task Force, the 2005
treatment recommendation remains in effect. To review the EvUp, see
[128_TD$IF]Supplement Appendix C-26.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are in respiratory failure who
undergo endotracheal intubation in any setting
 Intervention: The use of devices (eg, CO[13_TD$IF]2 detection device, CO2
analyser, or esophageal detector device)
 Comparator: Not using such a device
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2005.[132_TD$IF]
8181a,81b
The task force agreed to remove the weight minimum of 20 Kg
or greater for capnography. In addition, the task force noted that
continuous monitoring of waveform capnography has now become
routine in many settings.
Confirmation of tracheal tube position using exhaled CO2
detection (colorimetric detector or capnography) should be used for
intubated infants and children with a perfusing cardiac rhythm in all
settings (eg, out-of-hospital, emergency department, intensive care
unit, inpatient, operating room). In infants and children with a perfusing
rhythm, it may be beneficial to monitor continuous capnography or
frequent intermittent detection of exhaled CO2 during out-of-hospital
and intrahospital or interhospital transport.

Ventilation Rate With Advanced Airway During Cardiac
Arrest (PLS 3103A and PLS 382: EvUp)
The 2010 CoSTR was the most recent review of the evidence about
optimal minute ventilation (product of tidal volume and respiratory
rate/min) after the placement of an advanced airway during CPR in
infants or children. The minute ventilation recommended in the 2010
CoSTR was based on expert consensus.9,10

A155

137

This 2020 EvUp was to identify any evidence published after 2010
that might indicate the need for a new SysRev and for possible
modification of the current treatment recommendations. This EvUp
was prioritized for inclusion in this 2020 CoSTR because the task force
identified the differences in recommended or proposed minute
ventilation and respiratory rates across resuscitation councils and
sought to identify any evidence that could assist in the development of
a consistent recommended ventilation rate.
There was no evidence identified to support any specific ventilation
rate for the infant or child with inadequate ventilation and a perfusing
rhythm. The EvUp did identify a small single-center observational paper
that reported an association of ventilation rates higher that than 12 to 20/
min with improved outcomes.86 Ongoing studies are anticipated to
conclude later in 2020 that may provide further data. As a result, the PLS
Task Force will await the publication of more evidence to consider the
need for a SysRev and possible revision of the treatment recommendation. To review the EvUp, see [128_TD$IF]Supplement Appendix C-27.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with cardiac arrest and an
advanced airway
 Intervention: The use of a higher ventilation rate
 Comparator: The current recommendation of 8 to 10 breaths/min
 Outcome: ROSC, survival to discharge, survival with favourable
neurological status

Treatment Recommendations
The treatment recommendations are unchanged from 2010 except for
a minor edit to clarify types of arrest as asphyxial or arrhythmic (rather
than VF) in origin.9,10
After placement of a secure airway, avoid hyperventilation of
infants and children during resuscitation from cardiac arrest, whether
asphyxial or arrhythmic in origin.
A reduction in minute ventilation to less than baseline for age is
reasonable to provide sufficient ventilation to maintain adequate
ventilation-to-perfusion ratio during CPR while avoiding the harmful
effects of hyperventilation.
There are insufficient data to identify the optimal tidal volume or
respiratory rate.

PALS: Circulatory Support During CPR
Extracorporeal CPR for In-Hospital Cardiac Arrest (2019 CoSTR)
A SysRev about extracorporeal CPR (ECPR) for pediatric IHCA was
performed in 201887 and an ILCOR Pediatric CoSTR was published
as part of the 2019 CoSTR summary.71,72 The summary of the
consensus on science can be found in that 2019 CoSTR. Refer to
those publications for details of the evidence summary and task force
considerations.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Adults (age 18 years or older) and children (age
younger than 18 years) with cardiac arrest in any setting (out-ofhospital or in-hospital)
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 Intervention: Extracorporeal CPR (ECPR) including extracorporeal membrane oxygenator therapy or cardiopulmonary bypass
during cardiac arrest
 Comparator: Manual or mechanical CPR
 Outcome: Clinical outcomes, including short-term survival and
neurological outcomes (eg, hospital discharge, 28 days, 30 days,
and 1 month) and long-term survival and neurological outcomes
(eg, at 3 months, 6 months, and 1 year)
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to January 2019.
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 Comparator: No use of invasive monitoring to a specific systolic
and diastolic blood pressure
 Outcome: Change in survival to 180 days with good neurological
outcome, survival to 60 days with good neurological outcome,
survival to hospital discharge with good neurological outcome, the
likelihood of survival to discharge or ROSC
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.

Summary of Evidence
Treatment Recommendations
These treatment recommendations are unchanged from 2019.71,72
We suggest that ECPR may be considered as an intervention for
selected infants and children (eg, pediatric cardiac populations) with
IHCA refractory to conventional CPR in settings where resuscitation
systems allow ECPR to be well performed and implemented (weak
recommendation, very low-quality evidence).
There is insufficient evidence in pediatric OHCA to formulate a
treatment recommendation for the use of ECPR.

PALS: Physiological Monitoring During Arrest to
Guide Therapy and/or Intra-arrest
Prognostication
Physiological monitoring and feedback during CPR can facilitate the
adjustment of CPR delivery during resuscitation and, as a result, may
improve the quality of resuscitation and even resuscitation outcomes.
Such monitoring may also allow for “individualized CPR” tailored to the
patient’s needs and their responses to resuscitation interventions.
This section highlights the reviews about the use of invasive blood
pressure monitoring, bedside ultrasound, near-infrared spectroscopy,
and end-tidal carbon dioxide (ETCO2) to assist with the optimal
delivery of CPR.

Invasive Blood Pressure Monitoring During CPR (PLS 826:
ScopRev)
Rationale for Review
Maintenance of adequate arterial systolic (compression) and diastolic
(relaxation) or mean pressure during CPR is crucial to maintain
coronary and cerebral perfusion. Maintaining a sufficient minimum
threshold blood pressure should be associated with improved clinical
outcomes. It is unknown if CPR directed to meet individualized rather
than uniform standard blood pressure targets will improve outcomes
from cardiac arrest. This topic was most recently reviewed in
2015,11,12 and the 2020 ScopRev was performed to identify any
evidence on this topic published after 2015.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children undergoing CPR
 Intervention: Use of invasive hemodynamic monitoring to titrate to
a specific systolic and diastolic blood pressure

There was no association between blood pressures measured during
CPR and neurological outcomes in an observational study of survivors
of pediatric critical care (including cardiac critical care).88 In an
observational study of a highly selected pediatric critical care
population with arterial pressure monitoring in place when cardiac
arrest developed, there was a significant association between the
mean diastolic blood pressure of 25 mm Hg or greater in infants and
30 mm Hg or greater in children within the first 10 minutes postarrest
and their survival as well as with survival with favourable neurological
function.89 To review the ScopRev, see [128_TD$IF]Supplement Appendix B-5.

Task Force Insights
The information identified in this ScopRev applies only to pediatric
patients with intra-arterial access along with continuous monitoring of
blood pressure at the time they develop cardiac arrest. The work by
Berg and colleagues89 identified an association between the mean
diastolic blood pressure associated with neurologically intact survival
and the blood pressure thresholds below which no child survived. The
evidence was too limited, however, to consider the diastolic blood
pressure threshold by itself sufficient to identify CPR futility.
The PLS Task Force considered that, for children with IHCA and an
arterial line already in place, hemodynamic-directed CPR might be
considered. The task force agreed, however, that more evidence is
required and that there is insufficient evidence currently available to
consider a request for a SysRev. The 2015 treatment recommendation remains in effect.11,12

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
The confidence in effect estimates is so low that the panel decided
that a recommendation was too speculative.

Use of Near-Infrared Spectroscopy During Cardiac Arrest
(PLS New: ScopRev)
Rationale for Review
NIRS is a noninvasive mode of estimating regional cerebral and renal/
mesenteric oxygen saturation (rSO2) and can detect these signals in
no blood flow situations as in cardiopulmonary arrest. Cerebral NIRS
values can reflect cerebral physiological changes (ie, intracranial
tissue oxygenation that can be affected by arterial blood flow, tissue
perfusion, and venous drainage) during cardiac arrest, during
changes in intracranial pressure, during arrest resolution, and after
ROSC. NIRS uses adhesive sensors placed on the forehead (to
evaluate regional cerebral oxygen saturation of hemoglobin [rcSO2])
and over the abdomen. Each sensor contains a light source and 2
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fiberoptic bundles that can detect the light absorption and reflection at
different tissue depths.
This ScopRev addresses the use of NIRS as an intra-arrest
variable that may assist in tailoring CPR technique to improve blood
flow and oxygen delivery. The PLS Task Force has not previously
considered use of NIRS in this manner, hence there are no current
treatment recommendations. To review the ScopRev, see [128_TD$IF]Supplement Appendix B-6.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in any setting (in-hospital or outof-hospital) with cardiac arrest
 Intervention: The presence of variables—images, cut-off values,
or trends—during CPR (intra-arrest) that can provide physiological feedback to guide resuscitation efforts, namely NIRS and
cerebral oxygen saturation monitoring
 Comparator: The absence of such factors—images, cut-off
values, or trends
 Outcome: Any clinical outcome
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to October
2019.

Summary of Evidence
The ScopRev identified no pediatric RCTs but did identify 1 ongoing
adult RCT that compared the outcomes of NIRS-guided CPR with
current standard CPR practice (this study is anticipated to conclude in
2021) (NCT03911908) and 2 adult SysRevs. Both adult SysRevs
concluded that higher rSO2 was associated with higher likelihood of
ROSC and survival, whereas lower rcSO2 was associated with an
increased mortality.90,91 There was no consensus on the predictive
threshold value of rSO2 for any outcomes.92 94 A trend of rising rSO2
(between 7% and 15% from baseline measurement) may be a more
reliable predictive factor for ROSC.90,95,96
The ScopRev also identified 2 observational studies of NIRS in
children during CPR. One found that cerebral physiological changes
were associated with changed NIRS measurements during cardiac
arrest, increased intracranial pressure reduction, arrest resolution,
and after ROSC.97
The second small study found an association between higher
minimum rSO2 during CPR and ROSC,98 but overall survival was too
low to detect changes in survival. An adult observational study found [13_TD$IF]
ETCO2 to be a more accurate predictor of ROSC in OHCA.99

Task Force Insights
Survival after cardiac arrest may increase when resuscitation is
tailored to the cause of the arrest and to the patient’s responses to
treatment. The level of certainty about the use of NIRS is very low,
however, and the absence of consensus thresholds reduces its
usefulness. The value of monitoring trends in the rSO2 during pediatric
resuscitation still requires validation. The PLS Task Force agreed that
given the limited evidence available, there was currently insufficient
evidence to warrant consideration of a SysRev. As a result, there will
continue to be no treatment recommendation.
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Treatment Recommendations
No treatment recommendation has been made.

Bedside Ultrasound to Identify Perfusing Rhythm (PLS 408:
ScopRev)
Rationale for Review
This topic was most recently reviewed in the 2010 CoSTR
document.9,10 The PLS Task Force agreed that the increased use
of this technology warranted a ScopRev to determine any evidence
published after 2010. To review the ScopRev, see [128_TD$IF]Supplement
Appendix B-7.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in any setting (in-hospital or outof-hospital) with cardiac arrest
 Intervention: Point-of-care ultrasound (echocardiography during
cardiac arrest)
 Comparator:
Absence
of
point-of-care
ultrasound
(echocardiography)
 Outcome: Any clinical outcome
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and all languages were included if there was
an English abstract. This literature search was updated to May
2019.

Summary of Evidence
The PLS Task Force posed 3 questions for this ScopRev:
1 Can diagnostic images be reliably obtained by noncardiology
sonographers?
2 Can reversible causes of death be identified with high sensitivity
and specificity?
3 Can the procedure be used to predict outcome?
Echocardiography typically requires pauses in chest compressions,100 102 although the use of a protocol can reduce the duration of
these pauses.103,104 Practical difficulties in the use of ultrasound in
infants and children (that do not occur in adults) include small patient
size that may limit access to some views, particularly if other
monitoring pads are on the chest. In addition, abnormal cardiac
anatomy requires advanced training if noncardiac sonographers are
to derive helpful information in this setting.
There is very limited pediatric evidence documenting the use of
ultrasonography to identify reversible causes of arrest, for prognostication, or to determine cardiac futility. One small pediatric series of
high-risk children with ultrasound diagnosis of pulmonary emboli
resulted in successful thrombolytic therapy for all, with 80% survival to
hospital discharge.105 Complete cardiac standstill as determined
sonographically is unlikely to be used as a sign of futility during
pediatric resuscitation in light of case reports demonstrating that use
of ECPR resulted in viable cardiac function after cardiac standstill.106
Finally, significant cost is associated with the purchase of equipment
and training of users, which may limit its use in resource-limited
settings.
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Task Force Insights
The PLS Task Force agreed that they would not accept direct
extrapolation from adult studies of bedside ultrasonography because
there are substantial differences between adult and pediatric cardiac
arrest in terms of causes, anatomy, and technical matters—
challenges that could affect the usefulness and accuracy of the
ultrasound. Although the technology is widely used within the pediatric
critical care, emergency, and resuscitation communities, more data
detailing its advantages, pitfalls, and characteristics of performance
are needed so that its usefulness and limitations in pediatric cardiac
arrest can be fully defined.
In addition, there is inadequate pediatric evidence about its intraarrest prognostic utility, and the task force urges great caution until
more literature is available. See [128_TD$IF]Supplement Appendix B-7.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
There is insufficient evidence to recommend for or against the
routine use of bedside ultrasound and echocardiography during a
pediatric arrest. Ultrasonography may be considered to identify
potentially treatable causes of an arrest when appropriately skilled
personnel are available, but the benefits must be carefully weighed
against the known deleterious consequences of interrupting chest
compressions.

End-Tidal CO2 Monitoring During CPR (PLS 827: ScopRev)
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latter evidence is indirect, meaning that caution is needed in
extrapolating their findings to children. To review the ScopRev, see
[128_TD$IF]Supplement Appendix B-8.

Task Force Insights
The PLS Task Force agreed that it is important to identify measures to
improve the quality of CPR. Accurate monitoring of ETCO2 during
resuscitation, however, requires the insertion of an advanced airway;
an advanced airway insertion may produce undesirable effects (see
Ventilation During CPR With Bag and Mask Compared With an
Advanced Airway). The 2 pediatric observational studies identified by
the ScopRev included a subset of children in cardiac arrest, namely
those who were intubated in the intensive care unit at the time of arrest.
This is a very different population from infants and children with OHCA
or those who arrest in less specialized settings such as a less wellresourced general pediatric hospital setting or clinic.
The PLS Task Force agreed that the evidence for or against the
use of ETCO2 to guide resuscitation efforts and improve pediatric
cardiac arrest outcomes is insufficient to recommend consideration of
a SysRev. As a result, the 2015 treatment recommendation remains in
effect.11,12

Treatment Recommendations
This treatment recommendation (below) is unchanged from the
2015.11,12
The confidence in effect estimates is so low that the panel decided
that a recommendation was too speculative.

Rationale for Review
The PLS Task Force initially recommended end-tidal carbon dioxide
(ETCO2) monitoring to confirm tracheal tube placement in 2000.59
ETCO2 monitoring can also offer an indirect indication of cardiac
output and pulmonary blood flow (noting caveats in relation to
pulmonary blood flow and ventilation: perfusion ratio or with, for
example, rapid changes caused by deterioration or response to
effective treatment). As a result, ETCO2 has been proposed as a
method to evaluate the effectiveness of CPR and to identify possible
ROSC. A rapid increase in ETCO2 may be associated with improved
CPR (or ROSC), and a sustained decline or persistently low ETCO2
may be observed in the absence of ROSC. This 2020 ScopRev was
performed to identify the evidence available to support the use of
ETCO2 to provide feedback to guide resuscitation efforts.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in any setting (in-hospital or outof-hospital) with cardiac arrest
 Intervention: Presence of variables—images, cut-off values, or
trends—during CPR (intra-arrest) that can provide physiological
feedback to guide resuscitation efforts, namely ETCO[134_TD$IF]2
 Comparator: The absence of such factors—images, cut-off
values, or trends
 Outcome: Any clinical outcomes
 Time frame: All years and languages were included if there was an
English abstract. This literature search was updated to January
2020.

Summary of Evidence
The ScopRev identified only 2 pediatric observational studies,107,108
so the search was extended to include adult and animal literature. The

PALS: Resuscitation Drug Administration and
Timing
Drugs are used in resuscitation to support cardiovascular physiology
and organ perfusion and to ameliorate underlying pathophysiologic
processes to reduce morbidity and mortality. The medication topics
that were evaluated for 2020 included the optimal ways to calculate
body weight for prescribing medications dosed by weight, amiodarone
versus lidocaine for shock-resistant VF or pVT, and the role of sodium
bicarbonate and of calcium in the management of cardiopulmonary
arrest.

Methods of Calculating Pediatric Drug Doses (PLS 420:
EvUp)
The PLS Task Force last considered this topic in 2010.9,10 The search
performed for this EvUp identified multiple publications relating to
pediatric weight estimation, considering many different methods of
weight estimation. In light of the volume of pediatric publications
identified, the PLS Task Force agrees that there is sufficient evidence
to consider a request for a SysRev. Until the SysRev is completed and [1069_TD$IF]
analysed, the 2010 treatment recommendation remains in effect. To
review the EvUp, see [128_TD$IF]Supplement Appendix C-28.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Pediatric patients with cardiac arrest (prehospital
[OHCA] or in-hospital [IHCA])
 Intervention: The use of any specific alternative method for
calculating drug dosages
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 Comparator: Standard weight-based dosing
 Outcome: Achieving expected drug effect, ROSC, survival,
avoidance of toxicity
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to October
2019.

Treatment Recommendations
These treatment recommendations are unchanged from 2010.9,10
To calculate the dose of resuscitation medications, use the child’s
weight if known. If the child’s weight is unknown, it is reasonable to use
a body length tape with precalculated doses.
In nonobese pediatric patients, initial resuscitation drug doses
should be based on actual body weight (which closely approximates
ideal body weight). If necessary, body weight can be estimated from
body length.
In obese patients, the initial doses of resuscitation drugs should be
based on ideal body weight that can be estimated from length.
Administration of drug doses based on actual body weight in obese
patients may result in drug toxicity.
Subsequent doses of resuscitation drugs in both nonobese and
obese patients should take into account the observed clinical effects
and toxicities. It is reasonable to titrate the dose to the desired
therapeutic effect, but it should not exceed the adult dose.

Intraosseous Versus Intravenous Route of Drug
Administration (PLS, NLS, and ALS: SysRev)
Rationale for Review
This topic was last reviewed in 2010.9,10 A SysRev was requested to
identify evidence comparing effects of intraosseous with intravenous
drug administration during pediatric cardiac arrest. The PLS Task
Force joined with the ALS and NLS Task Forces in requesting the
SysRev.
Refer to the ALS and NLS publications in this supplement for
details of the evidence summary.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Pediatric patients in any setting (in-hospital or out-ofhospital) with cardiac arrest
 Intervention: Placement of an intraosseous (IO) cannula and drug
administration through this IO during cardiac arrest
 Comparator: Placement of an intravenous (IV) cannula and drug
administration through this IV during cardiac arrest
 Outcome: Return of spontaneous circulation, survival to hospital
discharge, and survival to hospital discharge with a favourable
neurological outcome
 Study design: Randomized trials, non-RCTs, and observational
studies (cohort studies and case-control studies) comparing IO
with IV administration of drugs included; randomized trials
assessing the effect of specific drugs (eg, epinephrine, amiodarone/lidocaine) in subgroups related to IO versus IV administration
also included
 Time frame: All years and languages were included if there was an
English abstract; unpublished studies (eg, conference abstracts,
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trial protocols) were excluded. The literature search was updated
to September 2019.

Consensus on Science
The SysRev identified no papers involving infants and children in
cardiac arrest. To review the adult evidence identified by the SysRev,
see the ALS publication in this supplement (ALS 2046: SysRev). To
review the neonatal evidence identified by the SysRev, see the
intraosseous versus umbilical vein for emergency access discussion
in the NLS publication of this supplement (NLS 616: SysRev).
The PLS Task Force agreed that, in the absence of new evidence,
the previous (2010) treatment recommendation should remain in
effect.9,10

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
Intraosseous cannulation is an acceptable route of vascular
access in infants and children with cardiac arrest. It should be
considered early in the care of critically ill children whenever venous
access is not readily available.

Epinephrine Time of Initial Dose and Dose Interval During
CPR (PLS 1541: SysRev)
Rationale for Review
Epinephrine administration for cardiac arrest was previously reviewed
in the 2015 CoSTR.11,12 The task force reported receiving many
questions about the effectiveness and timing of epinephrine
administration, so they requested a SysRev to identify any evidence
published after 2015 that could enable the formulation of a new
treatment recommendation. To review the SysRev, see [135_TD$IF]Supplement
Appendix A-2.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in cardiac arrest (in- or out-ofhospital) (excluding resuscitation at birth)
 Intervention: (1) Administration of the initial dose of epinephrine
earlier or later than current guideline recommendations. (2)
Administration of epinephrine more or less frequently than every 3
to 5 minutes following the initial dose
 Comparator: Timing of administration of epinephrine in line with
current guideline recommendations
 Outcome: Clinical outcomes, including short-term survival and
neurological outcomes (eg, hospital discharge, 28 days, 30 days,
and 1 month), and long-term survival and neurological outcomes
(eg, 3 months, 6 months, and 1 year)
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion; unpublished studies (eg, conference
abstracts, trial protocols) excluded
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to July 2019.
 PROSPERO Registration: Registered November 21, 2019. Final
registration number 146531.

Consensus on Science
We identified no pediatric RCTs on this topic. We did, however, identify
1 observational study of pediatric IHCA and 4 observational studies of
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OHCA comparing the administration of the initial dose of epinephrine
earlier or later than current guideline recommendations; we also
identified 2 observational studies of pediatric IHCA on the topic of
administration of epinephrine more or less frequently than every 3 to
5 minutes after the initial dose. We identified no observational studies
of pediatric OHCA addressing the interval between epinephrine
doses.

Time to First Epinephrine Less Than 15 Minutes Compared With
15 Minutes or More After Pediatric IHCA. For the critical outcomes
of survival with good neurological outcome, survival to discharge, or
ROSC, we identified 1 observational in-hospital registry study of 1558
children younger than 18 years with cardiac arrest.109 In multivariable
analysis, this study provided very low-certainty evidence (downgraded for risk of bias and imprecision) of no benefit associated with
first epinephrine dose less than 15 minutes compared with administration 15 minutes or more after cardiac arrest.

Time to First Epinephrine Less Than 10 Minutes Compared With
10 Minutes or More After Pediatric IHCA. For the critical outcome of
survival with good neurological outcome, we found an observational
study from the same database that identified 1395 pediatric patients
younger than 18 years of age with IHCA.109 In multivariable analysis,
the study provided very low-certainty evidence (downgraded for risk of
bias) of benefit associated with time to first epinephrine dose of less
than 10 minutes compared with 10 minutes or more after cardiac
arrest (RR, 3.37; 95% CI, 1.11 10.25; 113 more per 1000; 95% CI,
from 5 more to 440 more).
For the critical outcome of survival to discharge, we identified the
same observational study reporting outcomes of 1558 children with
IHCA.109 After multivariable analysis, this study provided very lowcertainty evidence (downgraded for risk of bias) of a benefit
associated with time to first epinephrine dose of less than 10 minutes
compared with 10 minutes or more after cardiac arrest (RR, 2.61; 95%
CI, 1.36 5.01; 198 more per 1000; 95% CI, from 44 more to 494
more).
For the critical outcome of 24-hour survival, we found the same
observational study of 1558 children with IHCA.109 In multivariable
analysis, the study provided very low-certainty evidence (downgraded
for risk of bias) of benefit associated with time to first epinephrine dose
less than 10 minutes compared with 10 minutes or more after cardiac
arrest (RR, 1.58; 95% CI, 1.09 2.28; 178 more per 1000; 95% CI,
from 28 more to 394 more).
For the critical outcome of ROSC, we found the same study of 1558
pediatric patients with IHCA.109 In multivariable analysis, this study
provided very low-certainty evidence (downgraded for risk of bias) of
benefit associated with time to first epinephrine dose of less than
10 minutes compared with 10 minutes or more after cardiac arrest
(RR, 1.56; 95% CI, 1.16 2.08; 233 more per 1000; 95% CI, from 66
more to 449 more).

Time to First Epinephrine Less Than 5 Minutes Compared With
5 Minutes or More After Pediatric IHCA. For the critical outcome of
survival with good neurological outcome, we identified the same
observational study reporting on outcomes of 1395 children younger
than 18 years with IHCA.109 In multivariable analysis, this study
provided very low-certainty evidence (downgraded for risk of bias) of
benefit of time to first epinephrine dose less than 5 minutes compared
with 5 minutes or more after cardiac arrest (RR, 1.74; 95% CI, 1.13
2.66; 71 more per 1000; 95% CI, from 12 more to 159 more).
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For the critical outcome of survival to discharge, we identified the
same observational study of reporting on 1558 pediatric patients with
IHCA.109 In multivariable analysis, this study provided very lowcertainty evidence (downgraded for risk of bias) of benefit associated
with time to first epinephrine dose less than 5 minutes compared with
5 minutes or more after cardiac arrest (RR, 1.57; 95% CI, 1.21 2.04;
120 more per 1000; 95% CI, from 44 more to 219 more).
For the critical outcome of 24-hour survival, we identified the same
observational study reporting on outcomes of 1558 children with
IHCA.109 In multivariable analysis, this study provided very lowcertainty evidence (downgraded for risk of bias) of benefit associated
with time to first epinephrine dose less than 5 minutes compared with
5 minutes or more (RR, 1.44; 95% CI, 1.20 1.73; 153 more per 1000;
95% CI, from 70 more to 254 more).
For the critical outcome of ROSC, we identified the same
observational study reporting on outcomes of 1558 pediatric patients
with IHCA.109 In multivariable analysis, this study provided very lowcertainty evidence (downgraded for risk of bias) of benefit associated
with time to first epinephrine dose less than 5 minutes compared with
5 minutes or more (RR, 1.29; 95% CI, 1.13 1.47; 149 more per 1000;
95% CI; from 67 more to 242 more).

Time to First Epinephrine Less Than 3 Minutes Compared With
3 Minutes or More After Pediatric IHCA. For the critical outcome of
survival with good neurological outcome, we identified 1 observational
study of 1395 pediatric patients with IHCA.109 In multivariable
analysis, this study provided very low-certainty evidence (downgraded for risk of bias) of benefit from time to first epinephrine dose
less than 3 minutes compared with 3 minutes or more (RR, 1.38; 95%
CI, 1.05 1.81; 48 more per 1000; 95% CI, from 6 more to 101 more).
For the critical outcome of survival to discharge, we identified the
same observational study of 1558 pediatric patients with IHCA.109 In
multivariable analysis, this study provided very low-certainty evidence
(downgraded for risk of bias) of benefit associated with time to first
epinephrine dose less than 3 minutes compared with 3 minutes or
more (RR, 1.38; 95% CI, 1.17 1.63; 95 more per 1000; 95% CI, from
43 more to 158 more).
For the critical outcome of 24-hour survival, we identified the same
observational study of 1558 pediatric patients with IHCA.109 In
multivariable analysis, this study provided very-low-certainty evidence (downgraded for risk of bias) of benefit associated with time to
first epinephrine dose less than 3 minutes compared with 3 minutes or
more (RR, 1.27; 95% CI, 1.13 1.43; 110 more per 1000; 95% CI, from
53 more to 175 more).
For the critical outcome of ROSC, we identified the same
observational study of 1558 pediatric patients with IHCA.109 In
multivariable analysis, this study provided very-low-certainty evidence (downgraded for risk of bias) of benefit associated with time to
first epinephrine dose less than 3 minutes compared with 3 minutes or
more (RR, 1.24; 95% CI, 1.13 1.35; 133 more per 1000; 95% CI, from
72 more to 195 more).

Time to First Epinephrine Less Than 15 Minutes Compared With
15 Minutes or More After Pediatric OHCA. For the critical outcome
of survival with good neurological outcome, we identified 2
observational studies of 725 pediatric patients 19 years or younger
with traumatic (509 children)110 and nontraumatic, nonshockable (216
children)111 OHCA. These studies provided very-low-certainty
evidence (downgraded for risk of bias, inconsistency, and imprecision), finding no benefit associated with a first dose of epinephrine less
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than 15 minutes compared with 15 minutes or more (RR, 3.94; 95% CI,
0.99 15.64; 80 more per 1000; 95% CI, from 0 fewer to 397 more).
For the critical outcome of survival to discharge, we identified 3
observational studies enrolling 27 480 children. These included
emergency medical services treated children younger than 18 years
with nonshockable arrest who did not experience ROSC within
10 minutes (26 755 children)112 and children 19 years or younger with
traumatic (509 children)110 and nontraumatic, nonshockable (216
children)111 OHCA. These studies provided very-low-certainty
evidence (downgraded for risk of bias, inconsistency, and other
considerations of large effect) of benefit associated with time to first
epinephrine dose less than 15 minutes compared with 15 minutes or
more (RR, 2.49; 95% CI, 1.30 4.77; 28 more per 1000; 95% CI, from 6
more to 70 more).
For the critical outcome of 30-day survival, we identified 1
observational registry study of 225 children between 1 and 17 years
with OHCA.113 This study provided very-low-certainty evidence
(downgraded for risk of bias, imprecision, and other considerations
of very large effect) of benefit associated with time to first epinephrine
dose less than 15 minutes compared with 15 minutes or more (RR,
5.78; 95% CI, 2.82 11.86; 348 more per 1000; 95% CI, from 133 more
to 791 more).
For the critical outcome of survival to intensive care unit admission,
we identified 1 observational study of 225 children 19 years or younger
with nontraumatic, nonshockable OHCA.111 This study provided verylow-certainty evidence (downgraded for risk of bias and imprecision)
of benefit associated with time to first epinephrine dose less than
15 minutes compared with 15 minutes or more (RR, 1.96; 95% CI, 1.37
2.81; 274 more per 1000; 95% CI, from 106 more to 517 more).
For the critical outcome of ROSC, we identified 2 observational
studies of 725 pediatric patients with traumatic110 and nontraumatic,
nonshockable111 OHCA. These studies provided very-low-certainty
evidence (downgraded for risk of bias and imprecision) of benefit
associated with time to first epinephrine dose less than 15 minutes
compared with 15 minutes or more (RR, 1.61; 95% CI, 1.37 1.90; 226
more per 1000; 95% CI, from 137 more to 334 more).

Time to First Epinephrine Less Than 10 Minutes Compared With
10 Minutes or More After Pediatric OHCA. For the critical outcome
of 30-day survival, we identified 1 observational study of 225 children
between 1 and 17 years with OHCA.113 This study provided very-lowcertainty evidence (downgraded for risk of bias, imprecision, and other
considerations of very large effect) of benefit associated with time to
first epinephrine dose less than 10 minutes compared with 10 minutes
or more (RR, 5.07; 95% CI, 1.20 21.42; 402 more per 1000; 95% CI,
from 20 more to 1000 more).
For the critical outcome of survival to discharge, we identified 1
observational study of 26 755 emergency medical service treated
children younger than 18 years with nonshockable OHCA arrest who
did not experience ROSC within 10 minutes.112 This study provided
very-low-certainty evidence (downgraded for risk of bias) of benefit
with time to first epinephrine dose less than 10 minutes compared with
10 minutes or more (RR, 1.55; 95% CI, 1.31 1.83; 9 more per 1000;
95% CI, from 5 more to 14 more).

Time to First Epinephrine Less Than 5 Minutes Compared With
5 Minutes or More After Pediatric OHCA. For the critical outcome of
survival to discharge, we identified 1 observational study of 26 755
emergency medical services treated children younger than 18 years
with nonshockable OHCA arrest who did not experience ROSC within

A155

143

10 minutes.112 This study provided very-low-certainty evidence
(downgraded for risk of bias) of benefit associated with time to first
epinephrine dose less than 5 minutes compared with 5 minutes or
more (RR, 1.81; 95% CI, 1.43 2.30; 16 more per 1000; 95% CI, from 9
more to 26 more).

Time to First Epinephrine Less Than 3 Minutes Compared With
3 Minutes or More After Pediatric OHCA. For the critical outcome of
survival to discharge, we identified 1 observational study of 26 755
emergency medical services treated children younger than 18 years
with nonshockable OHCA arrest who did not experience ROSC within
10 minutes.112 This study provided very-low-certainty evidence
(downgraded for risk of bias) of benefit associated with time to first
epinephrine dose less than 3 minutes compared with 3 minutes or
more (RR, 1.74; 95% CI, 1.14 2.67; 16 more per 1000; 95% CI, from 3
more to 35 more).

Epinephrine Dose Interval of Less Than 5 Minutes Compared With
5 Minutes or More for Pediatric IHCA. For the critical outcome of 12month survival, we identified 1 observational study of 235 pediatric
patients with IHCA who received 2 minutes or more of chest
compressions.114
This study represented a subset of all patients with IHCA because
it enrolled only patients who were eligible for the Therapeutic
Hypothermia After Pediatric Cardiac Arrest in-hospital (THAPCA-IH)
trial; the enrollees were all comatose and mechanically ventilated after
cardiac arrest, and the parents consented to enroll the children in the
trial. This study provided very low-certainty evidence (downgraded for
risk of bias, imprecision, and plausible confounding reducing
demonstrated effect) of lower 12-month survival associated with an
epinephrine dose interval of less than 3 minutes (adjusted OR 0.50;
95% CI, 0.24 1.06), 5 to less than 8 minutes (adjusted OR 0.42; 95%
CI, 0.20 0.89), or more than 8 minutes (adjusted OR 0.35; 95% CI,
0.16 0.75) compared with a 3 to less than 5-minute dose interval.
For the critical outcome of survival to discharge, we identified 1
observational in-hospital registry study of 1630 children with cardiac
arrest.115 This study provided very-low-certainty evidence (downgraded for risk of bias, imprecision, and plausible confounding
suggesting spurious effect) of benefit associated with more than 5minute to less than 8-minute dose intervals (adjusted OR [AOR], 1.81;
95% CI, 1.26 2.59) and 8 to less than 10 -minute intervals (AOR,
2.64; 95% CI, 1.53 4.55) compared with dose intervals of 1 to
5 minutes.
For the critical outcome of ROSC (survival of the IHCA event), we
identified the same observational study of 1630 children with IHCA.115
This study provided very-low-certainty evidence (downgraded for risk
of bias, imprecision, and plausible confounding suggesting spurious
effect) of benefit associated with more than 5 to less than 8 minute
dose intervals (AOR, 1.71; 95% CI, 1.27 2.31) and 8 to less than 10minute intervals (AOR, 1.93; 95% CI, 1.23 3.03) compared with dose
intervals of 1 to 5 minutes.
The same observational study of 1630 pediatric patients with IHCA
included a subset analysis of 1183 children who were not receiving
vasoactive infusions at the time of arrest.115 We identified very-lowcertainty evidence (downgraded for risk of bias, imprecision, and
plausible confounding suggesting spurious effect) of benefit associated with more than 5 to less than 8 minute dose intervals (AOR, 1.99;
95% CI, 1.29 3.06) and 8 to less than 10 -minute dose intervals (AOR,
2.67; 95% CI, 1.41 5.04) compared with dose intervals of 1 to
5 minutes.
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The same observational study of 1630 pediatric patients with IHCA
included a subset analysis of 447 children who were receiving
vasoactive infusions at the time of arrest.115 We identified very-lowcertainty evidence (downgraded for risk of bias, imprecision, and
plausible confounding suggesting spurious effect) of benefit associated with more than 5 to less than 8 minute dose intervals (AOR, 1.52;
95% CI, 0.77 3.02) and 8 to less than 10-minute intervals (AOR, 2.62;
95% CI, 0.85 8.07) compared with dose intervals of 1 to 5 minutes.

calculated the average interval of epinephrine doses by averaging all
doses within the total arrest time; this differs from the actual interval
between any 2 doses. For these reasons, the task force felt confidence
in the estimates of effect was too low to support a treatment
recommendation regarding epinephrine dose interval. For further
information, please refer to Supplement Appendix A-2.

Epinephrine Dose Interval of Less Than 3 Minutes Compared With
3 Minutes or More for Pediatric IHCA. For the critical outcome of 12-

Current knowledge gaps include but are not limited to: There is clinical
equipoise and the need for pediatric randomized trials addressing the
optimal timing of initial epinephrine dose and the optimal interval of
epinephrine doses. Researchers must establish a consistent method
to accurately calculate/report the interval between epinephrine doses.
There is a need to minimize the effects of resuscitation time bias in
resuscitation clinical trials.

month survival, we identified 1 observational study of 161 pediatric
patients with IHCA who were enrolled in the THAPCA-IH trial.114 This
study provided very-low-certainty evidence (downgraded for risk of
bias, imprecision, and plausible confounding reducing demonstrated
effect) of harm associated with a dose interval of less than 3 minutes
(AOR, 0.50; 95% CI, 0.24 1.06) as well as 5 to less than 8 minutes
(AOR, 0.42; 95% CI, 0.20 0.89) as well as 8 minutes or more (AOR,
0.5; 95% CI, 0.16 0.75) compared with a dose interval of 3 to less
than 5 minutes.

Treatment Recommendations
We suggest that the initial dose of epinephrine in pediatric patients
with nonshockable IHCA and OHCA be administered as early in the
resuscitation as possible (weak recommendation, very low-certainty
evidence).
We cannot make a recommendation for the timing of the initial
epinephrine dose in shockable pediatric cardiac arrest.
The confidence of the effect estimates is so low that we cannot
make a recommendation about the optimal interval for subsequent
epinephrine doses in pediatric patients with IHCA or OHCA.

[136_TD$IF]Justification and Evidence to Decision Framework
Highlights
Time to the Initial Dose of Epinephrine
In general, observational studies can be associated with many potential
biases. Resuscitation time bias often occurs in intracardiac arrest studies
such as epinephrine administration studies because the longer the
duration of the resuscitation, the lower the rate of survival. As a result,
patients who received the epinephrine earlier rather than later may have a
lower mortality for reasons other than the time of the epinephrine
administration.115a This bias can contribute to a trend toward appearance
of a harmful effect of later initial epinephrine doses. Therefore, when
interpreting studies of time to the initial dose of epinephrine the task force
considered the role of potential resuscitation time bias.

Knowledge Gaps

Amiodarone Versus Lidocaine for Shock-Resistant
Ventricular Fibrillation or Pulseless Ventricular Tachycardia
(2018 CoSTR)
The topic of amiodarone versus lidocaine for shock-resistant VF or
pVT was evaluated by the PLS Task Force in the 2018 CoSTR Update.[137_TD$IF]
115b,115c
xRefer to those publications for details of the evidence
summary and task force considerations.
The task force agreed that a multicenter trial comparing different
anti-arrhythmic agents would be helpful. Until further data are available,
the 2019 treatment recommendation remains in effect.[138_TD$IF]115b,115c

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Patients of all ages (neonates, children, adolescents
younger than 18 years) in any setting with cardiac arrest and a
shockable rhythm at any time during CPR or immediately after
ROSC
 Intervention: Administration (IV or IO) of an anti-arrhythmic drug
 Comparator: Another anti-arrhythmic or placebo
 Outcome: Survival to hospital discharge with good neurological
outcome, survival to hospital discharge, ROSC, and rearrest after
ROSC
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to August
2017.

Treatment Recommendations
Epinephrine Interval
Hoyme et al115 demonstrated that an increased epinephrine interval
was associated with a decreased probability of survival, with an
unadjusted odds ratio for survival of 0.60 for 5 to 8 minutes between
epinephrine doses, and 0.62 for 8 to 10 minutes between epinephrine
doses compared with 1 to 5 minutes between epinephrine dose.
However, in the adjusted statistical model, conversely, an increased
epinephrine interval was associated with an increased probability of
survival. The task force considered the fact that in the current metaanalysis, the unadjusted results, rather than the adjusted results were
incorporated. In addition, both Hoyme et al115 and Meert et al114

This treatment recommendation (below) is unchanged from [139_TD$IF]
2018.115b,115c
We suggest that amiodarone or lidocaine may be used for the
treatment of pediatric shock-resistant VF or pVT (weak recommendation, very low-quality evidence).

Sodium Bicarbonate Administration for Children in Cardiac
Arrest (PLS 388: EvUp)
The most recent PLS Task Force review of the evidence about sodium
bicarbonate administration during cardiac arrest was in 2010.9,10 An
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EvUp was performed and found insufficient evidence to consider a
SysRev of this topic, so the recommendations of 2010 remain in effect.
To review the EvUp, see [128_TD$IF]Supplement Appendix C-29.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are in cardiac arrest in any
setting
 Intervention: Buffering agent administration
 Comparator: No use of buffering agents
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
Routine administration of sodium bicarbonate is not recommended in the management of pediatric cardiac arrest.

Calcium Administration in Children (PLS 421: EvUp)
This EvUp was performed to identify any evidence published after the
most recent PLS Task Force review of this topic in 2010.9,10
The PLS Task Force agreed that there is insufficient evidence to
suggest the need for a SysRev or alter the 2010 treatment
recommendation, which remains in effect. To review the EvUp, see
[128_TD$IF]Supplement Appendix C-30.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who are in cardiac arrest in any
setting
 Intervention: Calcium administration
 Comparator: No calcium administration
 Outcome: All clinical outcomes
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was updated to November
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
Routine use of calcium for infants and children with cardiopulmonary
arrest is not recommended in the absence of hypocalcemia, calcium
channel blocker overdose, hypermagnesemia, or hyperkalemia.

PALS: Special Resuscitation Situations—Septic
Shock, Congenital Heart Disease, and Trauma
This section summarized the evidence reviews about resuscitation of
children with cardiac arrest and septic shock, congenital heart disease
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such as single-ventricle physiology, or Fontan circulation. The PLS
Task Force also reviewed the evidence about unique aspects of
resuscitation after traumatic arrest.

Resuscitation of the Child With Septic Shock (PLS 1534:
EvUp)
The management of children with septic shock associated cardiac
arrest has not been previously reviewed by the PLS Task Force. This
EvUp was requested to determine the available evidence about this
topic. The EvUp identified several studies involving prevention of
cardiac arrest, but there was insufficient evidence of unique
management approaches to the children with septic shock
associated cardiac arrest. As a result, the task force agreed that
there was no indication of a need to consider a SysRev, and no
treatment recommendation could be made at this time. To review the
EvUp, see [128_TD$IF]Supplement Appendix C-31.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children in cardiac arrest
 Intervention: Specific alteration in treatment algorithm
 Comparator: Standard care (according to 2010 treatment
algorithm)
 Outcome: All

Treatment Recommendation
There is no treatment recommendation at this time.

Resuscitation of the Patient With a Single Ventricle (PLS 390:
EvUp)
This EvUp was performed to identify any evidence published after the
most recent PLS Task Force review in 2010.9,10 The EvUp identified
nonrandomized studies reporting the impact of modification to
standard cardiac arrest care on outcomes in postsurgical infants.
The PLS Task Force agreed that this evidence[140_TD$IF]50,115d may warrant
consideration for a SysRev. Until a new SysRev is performed and [1069_TD$IF]
analysed by the PLS Task Force, the 2010 treatment recommendations remain in effect. To review the EvUp, see [128_TD$IF]Supplement
Appendix C-32.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with single-ventricle, status/post
stage I repair who require resuscitation from cardiac arrest or
prearrest states
 Intervention: Any specific modification to standard practice
 Comparator: Standard resuscitation practice
 Outcome: ROSC, survival to discharge, survival with good
neurological outcome
 Study design: Included only observational studies and RCTs from
the time of the previous search review
 Time frame: All years and languages were included if there was an
English abstract. The literature search was from January 2008 to
October 2019.
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Treatment Recommendations
These treatment recommendations are unchanged from 2010.9,10
Standard resuscitation (prearrest and arrest) procedures should
be followed for infants and children with single-ventricle anatomy after
stage I repair. Neonates with a single ventricle before stage I repair
who demonstrate shock caused by elevated pulmonary to systemic
flow ratio might benefit from inducing mild hypercarbia (PaCO2 50
60 mm Hg); this can be achieved during mechanical ventilation by
reducing minute ventilation, adding CO2 to inspired air, or administering opioids with or without chemical paralysis.

Resuscitation of the Patient With Hemi-Fontan or Fontan
Circulation (PLS 392: EvUp)
This EvUp was performed to identify any evidence about this topic
published after the PLS Task Force’s most recent review in 2010.9,10
The EvUp identified 1 registry-based study that reported outcomes of
infants and children with Fontan/ or bidirectional Glenn who had
circulatory support initiated during a peri-arrest phase.[14_TD$IF]115d The EvUp
identified no other relevant pediatric evidence.[142_TD$IF]50,115d The PLS Task
Force agreed that there is insufficient evidence to recommend a new
SysRev, and the 2010 treatment recommendation remains in effect,9,10
with the addition of a brief explanatory phrase within brackets. To review
the EvUp, see [128_TD$IF]Supplement Appendix C-33.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with Fontan or hemi-Fontan or
bidirectional Glenn circulation who require resuscitation from
cardiac arrest or prearrest states (prehospital or in-hospital)
 Intervention: Specific modification to standard resuscitation
practice
 Comparator: Standard resuscitation practice
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages were included if there was an
English abstract. The literature search was from January 2013 to
September 2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010 with
the exception of limiting the recommendation to children with hemiFontan9,10 or bidirectional Glenn physiology who are in a prearrest
state; hypercarbia achieved by hypoventilation may be beneficial to
increase oxygenation and cardiac output.
Negative-pressure ventilation, if available, may be beneficial for
children with either hemi-Fontan or bidirectional Glenn or Fontan
physiology by increasing cardiac output.
During cardiopulmonary arrest, it is reasonable to consider ECPR
for patients with Fontan physiology.
There is insufficient evidence to support or refute the use of ECPR
in patients with hemi-Fontan or bidirectional Glenn physiology.

Resuscitation After Traumatic Arrest (PLS 498: EvUp)
An EvUp was performed to identify any relevant studies published in
the decade after the 2010 PLS Task Force review of the topic.9,10 The
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PLS Task Force agreed that the evidence warrants consideration of a
SysRev, preferably one including not only adults but also infants and
children in the study population, to determine the evidence to support
specific recommendations about resuscitation for traumatic cardiac
arrest. To review the EvUp, see [128_TD$IF]Supplement Appendix C-34.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children with major (blunt or penetrating)
injury in cardiac arrest in any setting
 Intervention: Any specific alteration in treatment algorithm
 Comparator: Standard care (according to 2010 treatment
algorithm)
 Outcome: All
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages included if there was an
English abstract; literature search was updated to December
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2010.9,10
There is insufficient evidence to make a recommendation for
modification of standard resuscitation for infants and children
experiencing cardiac arrest due to major trauma, although consideration should be given to selectively performing a resuscitative
thoracotomy in children with penetrating injuries who arrive at the
hospital with a perfusing rhythm.

PALS: Post Cardiac Arrest Care, Including
Postarrest Prognostication
Targeted Temperature Management (2019 CoSTR)
A SysRev addressing targeted temperature management (TTM) was
published in 2019,116 and an ILCOR Pediatric CoSTR was published
as part of the 2019 CoSTR summary.71,72 Refer to those publications
for details of the evidence summary and task force considerations.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Pediatric patients (more than 24 hours to 18 years of
age) who achieved ROSC after OHCA or IHCA
 Intervention: TTM with a target temperature of 32  C to 36  C
 Comparator: No TTM or TTM at an alternative target temperature
range
 Outcome:
Primary outcome: Good neurobehavioral survival long term
Secondary outcomes:
o Good neurobehavioral survival short term and intermediate term
o Survival short term, intermediate term, and long term
o Neurobehavioral score changes from prearrest, intermediate
term, and long term
o Health-related quality of life score intermediate term and long term
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o Health-related quality of life score change from prearrest,
intermediate term, and long term
Additional in-hospital adverse outcomes:
o
o
o
o

Infection (culture proven)
Recurrent cardiac arrest (not leading to death)
Serious bleeding (red blood cell transfusion)
Arrhythmias (any)

Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
Time frame: All years and languages included if there was an
English abstract; literature search was updated to December 2018.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2019
(with the exception of the addition of “but remain comatose after OHCA
or IHCA” in the last line for clarity).
We suggest that for infants and children with OHCA, TTM be used
in the post cardiac arrest period to maintain a central temperature of
less than 37.5  C (weak recommendation, moderate-certainty
evidence).
On the basis of 2 randomized trials and 8 retrospective
observational cohort studies that provided comparative data on
favourable neurological outcome, survival, and in-hospital adverse
events, there is inconclusive evidence to support or refute the use of
TTM 32  C to 34  C compared with TTM 36  C to 37.5  C (or an
alternative temperature) for children who achieve ROSC but remain
comatose after OHCA or IHCA.

Oxygen and Carbon Dioxide Targets in Pediatric Patients
With Return of Spontaneous Circulation After Cardiac Arrest
(PLS 815: SysRev)
A SysRev of oxygen and carbon dioxide targets in adults and children
with ROSC after cardiac arrest[143_TD$IF]116a was conducted with involvement of
clinical content experts from the ALS and PLS Task Forces. Evidence
from adult and pediatric literature was sought and considered by the
ALS and PLS Task Forces, respectively. This CoSTR focuses on
evidence derived from infants and children. See [135_TD$IF]Supplement
Appendix A-2 for more details.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Unresponsive children with sustained return of
spontaneous circulation (ROSC) after cardiac arrest in any setting
 Intervention: A ventilation strategy targeting specific SpO[14_TD$IF]2
[oxygen saturation], PaO[145_TD$IF]2 [partial pressure of oxygen], and/or
PaCO[146_TD$IF]2 [partial pressure of carbon dioxide] targets
 Comparator: Treatment without specific targets or with an
alternate target to the intervention
 Outcome: Clinical outcome including survival/survival with a
favourable neurological outcome at hospital discharge/30 days,
and survival/survival with a favourable neurological outcome after
hospital discharge/30 days (eg, 90 days, 180 days, 1 year)
 Study design: Randomized trials, non-RCTs, and observational
studies (cohort studies and case-control studies) with a control
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group (ie, patients treated with no specific SpO2, PaO2, and/or
PaCO2 targets or an alternative target to the intervention) included
 Time frame: All years and languages included; literature search
was updated to August 2019.

Consensus on Science
Oxygen Targets. We identified no pediatric RCTs on this topic but did
identify 2 observational studies published in the 5 years after the
previous (2015) review.117,118 One of these118 was deemed at critical
risk of bias for lack of adjustment for cardiac arrest characteristics; for
this reason, interpretation of these results is severely limited. Within
these limitations, this study included 253 patients and found no
association between hyperoxemia and clinical outcomes in adjusted
analyses (numeric adjusted results not reported). Of all studies
identified (including those reviewed in 2015), only 3 pediatric
studies,117,119,120 including a total of 618 patients, were deemed to
have only serious risk of bias, and in all of these studies only adjusted
results were reported.
For the critical outcome of survival to hospital discharge with good
neurological outcome, we identified 1 observational study of 153
pediatric patients with ROSC after cardiac arrest.120 This study
provided very-low-certainty evidence (downgraded for indirectness,
imprecision, and risk of bias), finding no benefit of hyperoxemia
compared with no hyperoxemia (OR, 1.02; 95% CI, 0.46 2.27; 5 more
per 1000; 95% CI, from 170 fewer to 202 more).
For the critical outcome of survival to hospital discharge, we
identified 1 observational study of 164 pediatric patients with ROSC
after IHCA119 providing very low-certainty evidence (downgraded for
indirectness, imprecision, and very serious risk of bias) comparing
hyperoxemia with normoxemia and finding no benefit to hyperoxemia,
although numeric results of adjusted analyses were not reported. We
identified a second study of 200 pediatric patients with ROSC after
cardiac arrest117 that provided very low-certainty evidence (downgraded for indirectness, imprecision, and serious risk of bias) and that
showed no association of post-ROSC PaO2 greater than 200 mm Hg
with outcome (OR 0.81; 95% CI, 0.41 1.59; absolute risk difference
not calculable because the number of survivors in the normoxemia
group was not reported).
One large registry-based study121 found that hyperoxemia was
associated with higher mortality when compared with normoxemia.
Although this study was much larger than the others, it was deemed at
critical risk of bias as a result of lack of adjustment for cardiac arrest
characteristics (increasing the risk of confounding) and the exclusion
of the 31% of all eligible patients who lacked an arterial blood gas
analysis within 1 hour of ROSC. The task force thought that this
exclusion increased risk of selection bias because patients who did
not have an arterial blood gas analysis within 1 hour of ROSC are likely
disproportionally normoxemic or hyperoxemic rather than hypoxemic.

Carbon Dioxide Targets. We identified no pediatric RCTs on this
topic. Two observational studies were identified,118,119 1 of which118
was published in the interval after the search was completed for the
2015 CoSTR. Only adjusted results from these studies were reported.
One study119 including 223 patients provided very-low-certainty
evidence (downgraded for risk of bias and indirectness) of an increase
in hospital mortality associated with both hypocapnia (OR, 2.71; 95%
CI, 1.04 7.05; 242 more per 1000; 95% CI, from 9 more to 446 more)
and hypercapnia after ROSC (OR, 3.27; 95% CI, 1.62 6.61; 286
more per 1000; 95% CI, from 114 more to 423 more). The 1 study
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published after the 2015 review118 was deemed at critical risk of bias
for lack of adjustment for cardiac arrest characteristics. Within these
limitations, this study included 253 patients and found an increase in
hospital mortality associated with both hypocapnia compared with
normocapnia (OR, 2.62; 95% CI, 1.08 6.4; 233 more per 1000; 95%
CI, from 17 more to 429 more) and hypercapnia compared with
normocapnia (OR, 2.0; 95% CI, 1.01 3.97; 166 more per 1000; 95%
CI, from 2 more to 332 more) 1 hour after ROSC.
The available evidence on the effect of hypercapnia or hypocapnia
in adults is inconsistent, with the randomized trials done to date
showing no effect.

Treatment Recommendations
We suggest that rescuers measure PaO2 after ROSC and target a
value appropriate to the specific patient condition. In the absence of
specific patient data, we suggest rescuers target normoxemia after
ROSC (weak recommendation, very low-quality evidence).[147_TD$IF]1
[172_TD$IF]Given the availability of continuous pulse oximetry, targeting an
oxygen saturation of 94% to 99% may be a reasonable alternative to
measuring PaO2 and titrating oxygen when feasible to achieve
normoxia (based on expert opinion).
We suggest that rescuers measure PaCO2 after ROSC and target
normocapnia (weak recommendation, very low-certainty evidence).
Consider adjustments to the target PaCO2 for specific patient
populations where normocapnia may not be desirable (eg, chronic
lung disease with chronic hypercapnia, congenital heart disease with
single-ventricle physiology, increased intracranial pressure with
impending herniation).

Justification and Evidence to Decision Framework Highlights
Measurement of the arterial PaO2 and PaCO2 is much easier to
perform in the hospital than in the out-of-hospital setting. Yet without
such monitoring in the out-of-hospital setting, it will be difficult for
providers to judge within tolerable ranges the balance between
hypoxemia and hyperoxemia and between overventilation and
underventilation. These ranges of appropriate PaO2 and PaCO2 will
also differ for some patients, such as those with cyanotic congenital
heart disease.
In steady state situations (eg, steady temperature, PaCO2, and
pH), providers may be able to correlate the PaCO2 with the [13_TD$IF]ETCO2 to
determine trends that may provide information about ongoing
ventilatory responses to support ventilation.
The PLS Task Force recognized the paucity of data available to
make recommendations about target values for PaO2 and PaCO2 in
infants and children after ROSC.
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ROSC must be balanced against the risk of inadvertent hypoxemia
stemming from overzealous weaning of FiO2. Further challenges
include identifying the appropriate targets for specific pediatric patient
subpopulations (eg, infants and children with cyanotic heart disease).

Carbon Dioxide Targets. Accurate targeting of post-ROSC normocapnia might be achievable and acceptable in the in-hospital critical
care setting. Serial assessment of ventilation through arterial blood
gas analysis is facilitated by arterial catherization, which may also be
beneficial for targeting post-ROSC blood pressure targets. Correlation of PaCO2 and ETCO2 may allow ongoing monitoring of ventilation
when continuous capnography is available. Further challenges
include identifying any modified PaCO2 targets needed for specific
pediatric patient subpopulations (eg, infants and children with
suspected increased intracranial pressure).
For further information about task force development of treatment
recommendations from the published evidence on this topic, see the
evidence-to-decision table in [135_TD$IF]Supplement Appendix A-2.

Knowledge Gaps
The PLS Task Force identified the following knowledge gaps:
 There are no pediatric randomized trials comparing oxygen or
carbon dioxide management strategies in post cardiac arrest
care.
 We found no published evidence to determine how PaCO2 targets
should be adjusted in infants and children with chronic CO2
retention.
 We found no published evidence to determine whether adjusting
arterial blood gas analysis to 37 C or to a patient’s current
temperature is beneficial.

Post-ROSC Blood Pressure Control (PLS 820: EvUp)
This topic was most recently reviewed in 2015.11,12
This EvUp was performed to identify new evidence published in the
most recent 5 years. The EvUp identified evidence to suggest that post
cardiac arrest hypotension below the fifth percentile for age is
associated with poorer outcomes when compared with post cardiac
arrest normotension, and those patients requiring higher inotropic
drug support have lower rates of survival to hospital discharge. The
task force agreed that the EvUp identified sufficient new evidence to
suggest the need for a SysRev. Until such time as a SysRev is
completed and evaluated, the 2015 treatment recommendations
remain in effect.11,12 To review the EvUps, see [128_TD$IF]Supplement
Appendix C-35 and [128_TD$IF]Supplement Appendix C-36.

Oxygen Targets. Accurate targeting of post-ROSC normoxemia
might be achievable and acceptable being guided by pulse oximetry in
the hospital setting, but the use of pulse oximetry to titrate oxygen
administration to target normoxemia in the out-of-hospital setting has
not been studied and is not without risk of inadvertent patient
hypoxemia. Given the known risks of hypoxemia and the uncertain
risks of hyperoxia, any titration of oxygen delivery to children after

1

Note: This treatment recommendation applies to infants 28 days to 12
months and children in cardiac arrest. For recommendations applying to
newborns resuscitated at birth, refer to “Neonatal Life Support: 2020
International Consensus on Science on CPR and ECC Science With
Treatment Recommendations”[1074_TD$IF]7a,7b in the 2020 ILCOR CoSTR
supplement.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children after ROSC
 Intervention: Use of parenteral fluids and inotropes and/or
vasopressors to maintain targeted measures of perfusion such
as blood pressure
 Comparator: No use of these interventions
 Outcome: Patient satisfaction; survival with favourable neurological and functional outcome at discharge, 30 days, 60 days, 180
days, and/or 1 year; survival with favourable neurological and
functional outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival to hospital discharge; harm to patient
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 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages included if there was an
English abstract; literature search was updated to September
2019.

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
We recommend that for infants and children after ROSC, parenteral
fluids and/or inotropes or vasopressors should be used to maintain a
systolic blood pressure of at least greater than the fifth percentile for age
(strong recommendation, very low-quality evidence).
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arrest (weak recommendation, very low-quality evidence) ([148_TD$IF]Tables A1
and A2).

Topics Not Reviewed in 2020
Etomidate and pediatric septic shock (PLS 402)
Compression-only CPR for intubated neonates outside delivery
room (PLS 380)
Formulas for peds endotracheal tube size (PLS 401)
Endotracheal tube versus IV drugs (PLS 403)

Future Tasks
Post-ROSC Neuroprognostication and Use of
Electroencephalogram (PLS 813 and PLS 822: EvUp)
The most recent PLS Task Force review of post-ROSC predictive
factors was published in the 2015 CoSTR but was focused only on the
use of electroencephalography.11,12 This EvUp was performed to
determine if sufficient evidence exists to suggest the need for a
SysRev. The EvUp identified 8 studies reporting associations of
several factors in addition to electroencephalography with outcomes
after cardiac arrest.
The PLS Task Force agreed that this topic is of such interest that
they support the suggestion of a SysRev, with a broader search
strategy to include studies of additional potential prognostic indicators
beyond the electroencephalography. Until the SysRev is completed,
the 2015 treatment recommendation remains in effect.11,12 To [128_TD$IF]review
the EvUp, see Supplement Appendix C-37.

Population, Intervention, Comparator, Outcome, Study Design,
and Time Frame
 Population: Infants and children who have had cardiac arrests in
the hospital or out-of-hospital setting
 Intervention: Use of neuro-electrophysiology information (electroencephalography). Note: the PLS Task Force agreed that the list
of possible interventions or diagnostic tools must expand for the
next search.
 Comparator: None
 Outcome: Survival to 1 year with good neurological outcome,
survival to 180 days with good neurological outcome, survival to 60
days with good neurological outcome, survival to 6 months,
survival to 30 days with good neurological outcome, survival to 30
days with good neurological outcome, survival to hospital
discharge with good neurological outcome, survival with favourable neurological outcome, survival to hospital discharge
 Study design: RCTs and nonrandomized studies (non-RCTs,
interrupted time series, controlled before-and-after studies, cohort
studies) eligible for inclusion
 Time frame: All years and languages included if there was an
English abstract; literature search from January 2013 to August
2019

Treatment Recommendations
This treatment recommendation (below) is unchanged from 2015.11,12
We suggest that practitioners use multiple variables when
attempting to predict outcomes for infants and children after cardiac

The following PICOSTs will be prioritized for performing a SysRev.
The PLS Task Force will determine the timetabling for this body of
work.
Fluid administration in shock associated with dengue
Fluid administration in malaria with shock
Optimal timing for the administration of fluid resuscitation in
pediatric trauma
Prearrest care of the infant or child with dilated cardiomyopathy or
myocarditis (PLS 819: EvUp)
Prevention and management of pulmonary hypertensive crisis in
infants and children (PLS 391: EvUp)
Opioids, sedatives, and muscle relaxants for pulmonary hypertension (PLS 056: EvUp)
Therapy with inhaled nitric oxide or prostaglandin I2 for pulmonary
hypertensive crisis and right heart failure (2020 New EvUp)
CPR for heart rate of less than 60/min (PLS 1535: EvUp)
Energy doses for defibrillation (PLS 405: ScopRev)
Advanced airways: Cuffed versus uncuffed tubes (PLS 412: EvUp)
Resuscitation of the patient with a single ventricle (PLS 390: EvUp)
Resuscitation after traumatic arrest (PLS 498: EvUp)
Post-ROSC blood pressure control (PLS 820: EvUp)
Further work will be undertaken to look at diagnostic tests (PLS
411)
Effect of identification and preventive management of genetically
related family members of those with channelopathies on incidence of
cardiac arrest
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